

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/042418

International filing date: 16 December 2004 (16.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/530,102  
Filing date: 16 December 2003 (16.12.2003)

Date of receipt at the International Bureau: 26 January 2005 (26.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1275757

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*January 19, 2005*

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE.

APPLICATION NUMBER: 60/530,102

FILING DATE: *December 16, 2003*

RELATED PCT APPLICATION NUMBER: PCT/US04/42418



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

16152  
U.S. PTO

121603



PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. **EV 996371098 US**17510  
607530402  
U.S. PTO

INVENTOR(S)		
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
<b>Ari M.</b>	<b>Melnick</b>	<b>New York, NY</b>
Additional inventors are being named on the _____ -- separately numbered sheets attached hereto		
TITLE OF THE INVENTION (500 characters max)		
Direct all correspondence to: CORRESPONDENCE ADDRESS		
<input type="checkbox"/> Customer Number: _____		
OR		
<input checked="" type="checkbox"/> Firm or Individual Name <b>ARNOLD, Craig J.; GENDLOFF, Elie H.; MILLER, Alan D.</b>		
Address <b>AMSTER, ROTHSTEIN &amp; EBENSTEIN LLP</b>		
Address <b>90 Park Avenue</b>		
City <b>New York</b>	State <b>NY</b>	Zip <b>10016</b>
Country <b>US</b>	Telephone <b>212 336 8000</b>	Fax <b>212 336 8001</b>
ENCLOSED APPLICATION PARTS (check all that apply)		
<input checked="" type="checkbox"/> Specification Number of Pages <b>64</b>		<input type="checkbox"/> CD(s), Number _____
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets <b>10</b>		<input checked="" type="checkbox"/> Other (specify) <b>specification cover page; cover letter; return receipt postcard</b>
<input type="checkbox"/> Application Date Sheet. See 37 CFR 1.76		
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT		
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		FILING FEE Amount (\$)
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees.		
<input type="checkbox"/> The Director is hereby authorized to charge <b>additional</b> fees or credit any overpayment to Deposit Account Number: <b>01-1785</b>		<b>\$80.00</b>
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.		
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.		
<input checked="" type="checkbox"/> No.		
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____		

[Page 1 of 2]

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME **Elie H. Gendloff**TELEPHONE **212-336-8108**Date **December 16, 2003**REGISTRATION NO. **44,704**

(if appropriate)

Docket Number: **96700/846**

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT  
 This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**PROVISIONAL APPLICATION COVER SHEET**  
*Additional Page*

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number **96700/846**

**INVENTOR(S)/APPLICANT(S)**

Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
<b>Jonathan D.</b>	<b>Licht</b>	<b>Closter, NJ</b>
<b>Gilbert G.</b>	<b>Prive</b>	<b>Toronto, Canada</b>
<b>Khaja Farid</b>	<b>Ahmad</b>	<b>Toronto, Canada</b>

[Page 2 of 2]

Number 1 of 1

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

# AMSTER ROTHSTEIN & EBENSTEIN LLP

Intellectual Property Law

90 Park Avenue  
New York NY 10016  
Main 212 336 8000  
Fax 212 336 8001  
Web [www.arelaw.com](http://www.arelaw.com)



16152 U.S.PTO

*Partners*  
Morton Amster  
Jesse Rothstein (1934 - 2003)  
Daniel Ebenstein  
Philip Gottfried  
Michael J. Berger  
Neil M. Zipkin  
Anthony F. Lo Cicero  
Kenneth P. George  
Abraham Kasdan, Ph.D.  
Ira E. Silfin  
Chester Rothstein  
Craig J. Arnold

*Senior Counsel*  
Charles R. Macedo  
Mark J. Rosenberg  
Kenneth M. Bernstein  
*Of Counsel*  
Jerry D. Dainow  
*Associates*  
Neal L. Rosenberg  
Nancy M. Dodderidge  
Patrick Boland\*  
Trebor Lloyd  
Joseph M. Casino

John S. Economou  
Michael V. Solomita  
Holly Pekowsky  
Michael P. Kenney  
Marion P. Metelski\*  
Max Vern  
Dana R. Metes  
Karl J. Kolbinger  
Brian A. Comack  
Richard S. Mandaro  
Marc J. Jason  
Elie H. Gendloff, Ph.D.  
David Mitnick

Charles W. Rath  
David A. Boag  
Karen J. Bernstein  
Matthieu Hausig  
Jung S. Hahn  
Reiko Kaji  
Alan D. Miller, Ph.D.  
Hsin-Hsin (Ginger) Liu

\*Not admitted in New York

December 16, 2003

Elie H. Gendloff, Ph.D., Esq.  
Direct 212 336 8108  
e-mail [egendlof@arelaw.com](mailto:egendlof@arelaw.com)

## Via Express Mail

Mail Stop Provisional Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

"Express Mail" mailing label No. EV-996371098-US  
Date of Deposit: December 16, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name: Elie H. Gendloff

Signature:

Re: Rule 1.53(c) Provisional Patent Application Claiming Small Entity Status  
Title: METHODS AND COMPOSITIONS FOR INHIBITION OF  
BCL6 REPRESSION  
Inventors: Ari M. Melnick, Jonathan D. Licht, Gilbert G. Prive, and  
Khaja Farid Ahmad  
Our File: 96700/846

Dear Sir:

Pursuant to 37 C.F.R. §1.53(c), enclosed please find the following documents for filing with the above-identified provisional patent application claiming small entity status in the names of Ari M. Melnick, Jonathan D. Licht, Gilbert G. Prive, and Khaja Farid Ahmad, entitled GLP-1 (9-36) METHODS AND COMPOSITIONS FOR INHIBITION OF BCL6 REPRESSION, comprising the following:

1. Provisional Application For Patent Cover Sheet (Form PTO/SB/16) (2 pages);
2. Provisional patent application, including: application cover page (1 page), specification (57 pages), claims (6 pages), abstract (1 page), and drawings (10 sheets);

Commissioner for Patents  
Alexandria, VA 22313-4150  
Mail Stop Provisional Patent Application

-2-

December 16, 2003


3. Amster, Rothstein & Ebenstein LLP check in the amount of \$80.00 to cover the provisional application filing fee for small entity status; and
4. Return receipt postcard.

Please acknowledge receipt of the enclosed papers by stamping the enclosed postcard and returning the same to us.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicant  
90 Park Avenue  
New York, New York 10016  
212 336 8000

Dated: December 16, 2003  
New York, New York

By:   
Elie H. Gendloff  
Registration No. 44,704

New U.S. Provisional Patent Application (Small Entity Status)

**Title:** METHODS AND COMPOSITIONS FOR INHIBITION OF BCL6  
REPRESSION

**Inventors:** Ari M. Melnick, Jonathan D. Licht, Gilbert G. Prive, and  
Khaja Farid Ahmad

Express Mail EV 996371098 US

METHODS AND COMPOSITIONS FOR INHIBITION OF BCL6 REPRESSION

Statement Regarding Federally Sponsored Research or Development

The U.S. Government has a paid-up license in this invention and the right  
5 in limited circumstances to require the patent owner to license others on  
reasonable terms as provided by the terms of CA 59936 AM and R21 CA 99982,  
both awarded by the National Institutes of Health.

Background of the Invention

(1) Field of the Invention

10 The present invention generally relates to inhibition of corepressor  
binding to BCL6. More specifically, the invention is directed to compositions  
and methods for inhibiting corepressor binding to the BCL6 lateral groove.

(2) Description of the Related Art

References cited

15 Adams, J., Kelso, R., and Cooley, L. (2000). The kelch repeat superfamily  
of proteins: propellers of cell function. *Trends Cell Biol* 10, 17-24.

Ahmad, K. F., Engel, C. K., and Privé, G. G. (1998). Crystal structure of  
the BTB domain from PLZF. *Proc Natl Acad Sci U S A* 95, 12123-12128.

20 Albagli-Curiel, O. (2003). Ambivalent role of BCL6 in cell survival and  
transformation. *Oncogene* 22, 507-516.

Ball, H. J., Melnick, A., Shakhnovich, R., Kohanski, R. A., and Licht, J. D.  
(1999). The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a  
high molecular weight complex associated with cdc2 kinase. *Nucleic Acids Res*  
27, 4106-4113.

25 Ball, L. J., Jarchau, T., Oschkinat, H., and Walter, U. (2002). EVH1  
domains: structure, function and interactions. *FEBS Lett* 513, 45-52.

Bardwell, V. J., and Treisman, R. (1994). The POZ domain: a conserved protein-protein interaction motif. *Genes Dev* 8, 1664-1677.

Baron, B. W., Anastasi, J., Thirman, M. J., Furukawa, Y., Fears, S., Kim, D. C., Simone, F., Birkenbach, M., Montag, A., Sadhu, A. , et al. (2002). The 5 human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis. *Proc Natl Acad Sci U S A* 99, 2860-2865.

Brunger, A. T., Adams, P. D., Cloare, G. M., DeLano, W. L., Gros, P., 10 Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., and Pannu, N. S. (1998). Crystallography & NMR system: a new software suite for macromolecular structure determination. *Acta Crystallographica D54*, 905-921.

Calame, K. L., Lin, K. I., and Tunyaplin, C. (2003). Regulatory mechanisms that determine the development and function of plasma cells. *Annu Rev Immunol* 21, 205-230.

Costoya, J. A., and Pandolfi, P. P. (2001). The role of promyelocytic leukemia zinc finger and promyelocytic leukemia in leukemogenesis and development. *Curr Opin Hematol* 8, 212-217.

Cull, M. G., and Schatz, P. J. (2000). Biotinylation of proteins *in vivo* and 20 *in vitro* using small peptide tags. *Methods Enzymol* 326, 430-440.

David, G., Alland, L., Hong, S. H., Wong, C. W., DePinho, R. A., and Dejean, A. (1998). Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. *Oncogene* 16, 2549-2556.

Deltour, S., Guerardel, C., and Leprince, D. (1999). Recruitment of 25 SMRT/NCoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B. *Proc Natl Acad Sci U S A* 96, 14831-14836.

Dent, A. L., Vasanwala, F. H., and Toney, L. M. (2002). Regulation of 30 gene expression by the proto-oncogene BCL-6. *Crit Rev Oncol Hematol* 41, 1-9.

Dhordain, P., Albagli, O., Ansieau, S., Koken, M. H., Deweindt, C., Quief, S., Lantoine, D., Leutz, A., Kerckaert, J. P., and Leprince, D. (1995). The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to nuclear dots and mediates homomerisation in vivo. *Oncogene* 11, 2689-2697.

5 Dhordain, P., Albagli, O., Lin, R. J., Ansieau, S., Quief, S., Leutz, A., Kerckaert, J. P., Evans, R. M., and Leprince, D. (1997). Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. *Proc Natl Acad Sci U S A* 94, 10762-10767.

Dhordain, P., Lin, R. J., Quief, S., Lantoine, D., Kerckaert, J. P., Evans, R.

10 M., and Albagli, O. (1998). The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. *Nucleic Acids Res* 26, 4645-4651.

Fearon, D. T., Manders, P., and Wagner, S. D. (2001). Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. *Science*

15 293, 248-250.

Frankel, A. D. and Pabo, C. O. (1988). *Cell* 23, 1189-1193.

Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I. , et al. (1998). Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in

20 promyelocytic leukaemia. *Nature* 391, 815-818.

Guidez, F., Ivins, S., Zhu, J., Soderstrom, M., Waxman, S., and Zelent, A. (1998). Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. *Blood* 91, 2634-2642.

25 Hamilton, A. C., Inglese, J., and Ferrer, M. (2003). A PDZ domain-based assay for measuring HIV protease activity: Assay design considerations. *Protein Sci* 12, 458-467.

He, L. Z., Guidez, F., Tribioli, C., Peruzzi, D., Ruthardt, M., Zelent, A., and Pandolfi, P. P. (1998). Distinct interactions of PML-RARalpha and

PLZFRARalpha with co- repressors determine differential responses to RA in APL. *Nat Genet* 18, 126-135.

Hong, S. H., David, G., Wong, C. W., Dejean, A., and Privalsky, M. L. (1997). SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. *Proc Natl Acad Sci U S A* 94, 9028-9033.

Huynh, K. D., and Bardwell, V. J. (1998). The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. *Oncogene* 17, 2473-2484.

Huynh, K. D., Fischle, W., Verdin, E., and Bardwell, V. J. (2000). BCoR, a novel corepressor involved in BCL-6 repression. *Genes Dev* 14, 1810-1823.

Kaplan, J., and Calame, K. (1997). The ZIN/POZ domain of ZF5 is required for both transcriptional activation and repression. *Nucleic Acids Res* 25, 1108-1116.

Kay, B. K., Williamson, M. P., and Sudol, M. (2000). The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. *FASEB J* 14, 231-241.

Kobayashi, A., Yamagiwa, H., Hoshino, H., Muto, A., Sato, K., Morita, M., Hayashi, N., Yamamoto, M., and Igarashi, K. (2000). A combinatorial code for gene expression generated by transcription factor Bach2 and MAZR (MAZ-related factor) through the BTB/POZ domain. *Mol Cell Biol* 20, 1733-1746.

Kreusch, A., Pfaffinger, P. J., Stevens, C. F., and Choe, S. (1998). Crystal structure of the tetramerization domain of the Shaker potassium channel. *Nature* 392, 945-948.

Kuppers, R., and Dalla-Favera, R. (2001). Mechanisms of chromosomal translocations in B cell lymphomas. *Oncogene* 20, 5580-5594.

Ladbury, J. E., Lemmon, M. A., Zhou, M., Green, J., Botfield, M. C., and Schlessinger, J. (1995). Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal. *Proc Natl Acad Sci U S A* 92, 3199-3203.

Lemercier, C., Brocard, M. P., Puvion-Dutilleul, F., Kao, H. Y., Albagli, O., and Khochbin, S. (2002). Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. *J Biol Chem* 277, 22045-22052.

Li, J. Y., English, M. A., Ball, H. J., Yeyati, P. L., Waxman, S., and Licht, J.

5 D. (1997). Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein. *J Biol Chem* 272, 22447-22455.

Li, X., Peng, H., Schultz, D. C., Lopez-Guisa, J. M., Rauscher, F. J., 3rd, and Marmorstein, R. (1999). Structure-function studies of the BTB/POZ transcriptional repression domain from the promyelocytic leukemia zinc finger 10 oncoprotein. *Cancer Res* 59, 5275-5282.

Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., Jr., and Evans, R. M. (1998). Role of the histone deacetylase complex in acute promyelocytic leukaemia. *Nature* 391, 811-814.

Lin, R. J., Sternsdorf, T., Tini, M., and Evans, R. M. (2001).

15 Transcriptional regulation in acute promyelocytic leukemia. *Oncogene* 20, 7204-7215.

Mahmoudi, T., Katsani, K. R., and Verrijzer, C. P. (2002). GAGA can mediate enhancer function in trans by linking two separate DNA molecules. *EMBO J* 21, 1775-1781.

20 Melnick, A., Ahmad, K. F., Arai, S., Polinger, A., Ball, H., Borden, K. L., Carlile, G. W., Privé, G. G., and Licht, J. D. (2000). In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions. *Mol Cell Biol* 20, 6550-6567.

25 Melnick, A., Carlile, G., Ahmad, K. F., Kiang, C. L., Corcoran, C., Bardwell, V., Privé, G. G., and Licht, J. D. (2002). Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. *Mol Cell Biol* 22, 1804-1818.

Melnick, A., and Licht, J. D. (1999). Deconstructing a disease: RARalpha, 30 its fusion partners, and their roles in the pathogenesis of acute promyelocytic

leukemia. *Blood* 93, 3167-3215.

Niu, H. (2002). The proto-oncogene BCL-6 in normal and malignant B cell development. *Hematol Oncol* 20, 155-166.

Niu, H., Cattoretti, G., and Dalla-Favera, R. (2003). BCL6 Controls the  
5 Expression of the B7-1/CD80 Costimulatory Receptor in Germinal Center B Cells. *J Exp Med* 198, 211-221.

Otwinowski, Z., and Minor, W. (1997). Processing of X-ray diffraction data collected in oscillation mode. *Methods in Enzymology: Macromolecular Crystallography Part A* 276, 307-326.

Pasqualucci, L., Migliazza, A., Basso, K., Houldsworth, J., Chaganti, R. S., and Dalla-Favera, R. (2003). Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. *Blood* 101, 2914-2923.

Pawson, T., and Nash, P. (2003). Assembly of cell regulatory systems  
15 through protein interaction domains. *Science* 300, 445-452.

Prehoda, K. E., Lee, D. J., and Lim, W. A. (1999). Structure of the enabled/VASP homology 1 domain-peptide complex: a key component in the spatial control of actin assembly. *Cell* 97, 471-480.

Scheldrick, G. M., and Schneider, T. R. (1997). SHELXL: high-resolution  
20 refinement. *Methods Enzymol* 277, 319-343.

Shaffer, A. L., Lin, K. I., Kuo, T. C., Yu, X., Hurt, E. M., Rosenwald, A., Giltnane, J. M., Yang, L., Zhao, H., Calame, K., and Staudt, L. M. (2002). Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. *Immunity* 17, 51-62.

Shaffer, A. L., Yu, X., He, Y., Boldrick, J., Chan, E. P., and Staudt, L. M.  
25 (2000). BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. *Immunity* 13, 199-212.

Shen, H. M., Peters, A., Baron, B., Zhu, X., and Storb, U. (1998). Mutation of BCL-6 gene in normal B cells by the process of somatic  
30 hypermutation of Ig genes. *Science* 280, 1750-1752.

Staudt, L. M. (2002). Gene expression profiling of lymphoid malignancies. *Annu Rev Med* 53, 303-318.

Stebbins, C. E., Kaelin, W. G., Jr., and Pavletich, N. P. (1999). Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. *Science* 284, 455-461.

Sudol, M., Sliwa, K., and Russo, T. (2001). Functions of WW domains in the nucleus. *FEBS Lett* 490, 190-195.

Terwilliger, T. C., and Berendzen, J. (1999). Automated MAD and MIR structure solution. *Acta Crystallogr D Biol Crystallogr* 55 ( Pt 4), 849-861.

Toney, L. M., Cattoretti, G., Graf, J. A., Merghoub, T., Pandolfi, P. P., Dalla- Favera, R., Ye, B. H., and Dent, A. L. (2000). BCL-6 regulates chemokine gene transcription in macrophages. *Nat Immunol* 1, 214-220.

Wang, X., Li, Z., Naganuma, A., and Ye, B. H. (2002). Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. *Proc Natl Acad Sci U S A* 99, 15018-15023.

Wong, C. W., and Privalsky, M. L. (1998). Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6. *J Biol Chem* 273, 27695-27702.

Ye, B. H. (2000). BCL-6 in the pathogenesis of non-Hodgkin's lymphoma. *Cancer Invest* 18, 356-365.

Zelent, A., Guidez, F., Melnick, A., Waxman, S., and Licht, J. D. (2001). Translocations of the RARalpha gene in acute promyelocytic leukemia. *Oncogene* 20, 7186-7203.

Zhang, H., Okada, S., Hatano, M., Okabe, S., and Tokuhisa, T. (2001). A new functional domain of Bcl6 family that recruits histone deacetylases. *Biochim Biophys Acta* 1540, 188-200.

The BTB domain is a highly conserved, widely distributed protein-protein interaction motif found in a family of transcription factors that play critical roles in cellular differentiation, development and neoplasia. Several BTB/zinc finger

proteins, including B-cell lymphoma 6 (BCL6) and promyelocytic leukemia zinc finger (PLZF), are transcriptional repressors that are implicated in human malignancy (Albagli-Curiel, 2003; Costoya and Pandolfi, 2001; Dent et al., 2002; Lin et al., 2001; Melnick and Licht, 1999). Both the BCL6 and PLZF

5 proteins consist of an N-terminal BTB domain, followed by a central region of several hundred residues that are predicted to have little or no fixed 3D structure, and end with a series of C<sub>2</sub>H<sub>2</sub>-type zinc finger domains at the C-terminus. This general type of architecture is seen in 43 of the over 200 known human BTB domain proteins (GGP and P.J. Stogios,

10 [http://xtal.uhnres.utoronto.ca/prive/btb\\_database.html](http://xtal.uhnres.utoronto.ca/prive/btb_database.html)). A second major class of BTB domain proteins contain C-terminal kelch β-propeller repeats, and many of these are thought to be involved cytoskeletal functions, although some of these are involved in transcription regulation (Adams et al., 2000). The core BTB domain fold is also found in the T1 domain of voltage-gated K<sup>+</sup> channels

15 (Kreusch et al., 1998), and in the ElonginC/Skp1 proteins (Stebbins et al., 1999).

Despite the architectural similarity of the BTB/zinc finger transcription factors, these can function as repressors, activators, or both and the BTB domain plays a central role in these activities (Kaplan and Calame, 1997; Kobayashi et al., 2000; Mahmoudi et al., 2002). The majority of BTB/zinc finger proteins, however, are thought to be transcriptional repressors, and several of these mediate their effects through the recruitment of histone deacetylase complexes. Thus, in BCL6, the BTB domain mediates interactions with the SMRT, N-CoR, BCoR and mSin3A corepressors, as well as with histone deacetylase 1

20 (HDAC-1), and repression is relieved with HDAC inhibitors (David et al., 1998; Dhordain et al., 1997; Dhordain et al., 1998; Grignani et al., 1998; Guidez et al., 1998; He et al., 1998; Hong et al., 1997; Huynh and Bardwell, 1998; Huynh et al., 2000; Lin et al., 1998; Wong and Privalsky, 1998). The recruitment of a histone deacetylase complex is not a universal property of the BTB domain, as

25 evidenced by the fact that the BTB domains of HIC1 and gFBP-B do not interact

with these factors (Deltour et al., 1999). Thus, it is clear that distinct mechanisms are used by different BTB domains in order to carry out a variety of biological effects.

In the B-cell lineage, the BCL6 protein is expressed in germinal center

5 (GC) B-cells, but not in pre-B cells or in differentiated progenies such as plasma cells. Because BCL6 expression is tightly regulated during lymphoid differentiation, its down-regulation in post-GC B-cells may be necessary for further plasma/memory cell differentiation. Some of the more notable genes that are repressed by BCL6 include the B lymphocyte-induced maturation

10 protein (blimp-1), a transcriptional repressor of c-myc which plays a key role in differentiation of B-cells to plasma cells (Shaffer et al., 2002), the cell cycle control genes p27kip1 and cyclin D2 (Shaffer et al., 2000), the programmed cell death-2 protein (PDCD2) (Baron et al., 2002), and B7-1/CD80 (Niu et al., 2003). Chromosomal translocations upstream of the BCL6 gene are observed in

15 approximately 30-40% of diffuse large B-cell lymphomas (DLBCL) and in 5-14% of follicular lymphomas (FL) (Kuppers and Dalla-Favera, 2001; Niu, 2002; Ye, 2000). In addition, the promoter region of BCL6 is targeted by somatic hypermutation in GC B-cells (Pasqualucci et al., 2003; Shen et al., 1998; Wang et al., 2002). Thus, a B-cell with an activated BCL6 gene may be trapped at the

20 GC stage due to the repression of differentiation and cell-cycle control proteins (Calame et al., 2003; Dent et al., 2002; Fearon et al., 2001; Staudt, 2002). In addition to its role in lymphoid cells, BCL6 represses the expression of the chemokines MCP-1, MCP3 and MRP-1 in macrophages and is an important negative regulator of TH-2 type inflammation (Toney et al., 2000).

25 Summary of the Invention

Accordingly, the invention is based on the identification of the BCL6 site of corepressor binding, and the discovery that peptides having the sequence of the corepressor binding site inhibit corepressor binding to BCL6. This inhibition causes apoptosis of B-cell lymphoma cells expressing BCL6.

Thus, in some embodiments, the invention is directed to compounds that are capable of blocking corepressor binding to a BCL6 lateral groove. Preferred compounds are peptides or mimetics that comprise the sequence eipx, where x is a basic amino acid or analog. The most preferred compounds comprise the 5 sequence of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3.

The invention is also directed to methods of blocking corepressor binding to the BCL6 lateral groove binding. The methods comprise contacting the BCL6 with any of the above-described compounds.

The invention is additionally directed to methods of inhibiting BCL6 10 repression in a mammalian cell. The methods comprise treating the cell with any of the above-described compounds.

In additional embodiments, the invention is directed to methods of treating a mammal with cancer, where the cancer requires BCL6 repression. The methods comprise administering any of the above-described compounds, in 15 a pharmaceutically acceptable excipient, to the mammal.

The invention is also directed to methods of identifying a compound that inhibits corepressor binding to BCL6. The methods comprise identifying a compound that binds to a BCL6 lateral groove, where such a compound inhibits copressor binding to BCL6.

## 20 Brief Description of the Drawings

FIG. 1 is two diagrams and a graph showing the structure of the BCL6 BTB domain. Panel A is a ribbon diagram of the BCL6 BTB dimer (form I crystal). Panel B shows the superposition of single chains from various BTB domains structures. In all cases, the BTB domain forms highly similar 25 homodimers. Panel C shows the results of reporter assays performed in 293 T cells comparing transcriptional repression mediated by escalating doses of vectors expressing the GAL4 DNA binding domain fused to the BTB domain from wild-type BCL6 ( $BTB^{BCL6-wt}$ ), C8Q/C67R/C84N cysteine substituted BCL6 ( $BTB^{BCL6-3C}$ ), or PLZF ( $BTB^{PLZF}$ ).

FIG 2 is a photograph, diagrams and graphs establishing the identification of the minimal BCL6 BTB interaction fragment in SMRT. Panel A is a photograph of a stained gel of SMRT or N-CoR fragments expressed as His-tagged thioredoxin (Trx) fusion proteins, purified, and mixed with purified BCL6 BTB domain. Complexes were affinity purified over Ni-NTA columns and separated by SDS-PAGE. Lane a: purified Trx-N-CoR<sup>1351-1383</sup>; lane b: purified BCL6 BTB domain; lanes c-j: copurifications of BCL6 BTB domain with the His-tagged corepressor fusion proteins described in panel B. Panel B is diagrams showing the “IS” and “AAAA” substitution mutations replacing SMRT residues 1424-1425, and 1427-1430, respectively. The open box represents the minimal binding domain. Panel C is SPR sensograms showing the binding of the BCL6 BTB domain at the indicated concentrations to immobilized SMRT<sup>1414-1441</sup> peptide (fragment d). Panel D is a graph of relative affinities of the BCL6 BTB domain for the corepressor fragments described in panel B. The data are presented as ratios of the dissociation constants relative to SMRT<sup>1414-1441</sup> (fragment d), as measured by SPR. “N.b.” indicates no detectable binding. Panel E is a graph of ITC titration of SMRT<sup>1414-1430</sup> to a solution of BCL6 BTB domain.

FIG. 3 is diagrams showing the structure of the BCL6 BTB domain / SMRT-BBD complex. Panel A is a ribbon diagram of the 2:2 complex. The crystallographic asymmetric unit contains the entire four-chain structure. The two chains of the BCL6 BTB domain dimer are colored blue and red, and the two SMRT chains are colored yellow and green. The N-termini of the two SMRT chains are labeled. Panels B, C and D shows views of the BCL6 BTB domain displayed as a solvent accessible surface colored according to the two chains of the BTB dimer (blue and white), with the two SMRT fragments rendered in stick representation (oxygens in red, nitrogens in blue, and the carbons of the two corepressor chains colored in either yellow or green, as in panel A. The two non-overlapping surfaces of the BCL6 BTB dimer that are buried upon peptide binding are highlighted in purple. Panel B is a view in the

same orientation as in panel A. Panel C shows the “bottom” of the complex, viewed along the molecular pseudo-twofold axis. Panel D shows that Ser-1424 (hidden by His-116 in this view) and Ile-1425 of SMRT are buried in a groove formed in part by Arg-13' ( $\alpha 1'$ ) and His-116 ( $\alpha 6$ ) from the two chains of the  
5 BCL6 BTB domain. Panel E shows the sequence alignment of selected human BTB/zinc finger proteins and the observed secondary structure of the BCL6 BTB domain. The residue-by-residue surfaces buried due to interactions with the yellow SMRT peptide are indicated with red and blue bars (color scheme according to panel A). HIC-1 has a 13 amino acid insert at the position  
10 indicated by the three asterixes.

FIG. 4 is illustrations and a photograph showing relevant peptide binding interactions. Panel A shows a schematic drawing of the contacts between the BCL6 BTB domain and the “yellow” SMRT chain (colors as in FIG. 3A). Nearly identical contacts are observed in the other contact surface. Panel B shows a  
15 highlight of the interactions between SMRT 1427-1430 and the BCL6 BTB domain. Panel C shows interactions of SMRT 1424-1426 with the BCL6 BTB domain. In panel D, to view the interactions between region 1414-1423 of the SMRT-BBD peptide and BTB  $\beta 1'$ , the BCL6 helix  $\alpha 6$  (red chain) has been made transparent. Panel E shows the superposition of the two crystallographically  
20 independent SMRT peptides from the complex, with carbons shown in yellow and green as in FIG. 3. The six waters from each site that participate in the bridging SMRT/BCL6 interactions are indicated as yellow or green spheres. Panel F is a photograph of a gel showing that mutations in the BCL6 BTB peptide binding pocket reduce the affinity for the SMRT peptide. His-tagged  
25 Trx-(SMRT-BBD) was mixed with three different forms of the BCL6 BTB domain, and the load (“L”), flow through (“FT”), wash (“W”) and elute (“E”) fractions from each co-purification trial were analyzed by SDS-PAGE.

FIG. 5 is graphs, photographs and micrographs showing that the SMRT-BBD motif interacts with the BCL6 BTB domain *in vivo*. Mammalian two  
30 hybrid assays were performed in 293 T cells by cotransfected the indicated

expression vectors along with 100 ng of a (GAL4)<sub>5</sub>-TK-Luc reporter and 12.5 ng of a TK-renilla internal control plasmid. Panel A is a graph of experimental results where 25 ng of bait GAL4<sup>1-147</sup> or GAL4-BCL6<sup>BTB</sup> plasmid were transfected either alone or in combination with 300 ng of prey VP16-(SMRT-BBD) fusions.

5 Results are shown as relative luciferase units to show both repression and activation. Panel B is a graph of experimental results where 25 ng of bait plasmid expressing GAL4<sup>1-147</sup> alone or fused to wild type or mutant BCL6 BTB domains were cotransfected along with 300 ng of prey plasmid expressing VP16-full-length SMRT fusions. Panel C shows GAL4 immunoblots of 293T cells

10 transfected with 100 ng of wild-type or mutant GAL4-BTB<sup>BCL6</sup> plasmids. Panel D shows VP16 immunoblots of 293T cells transfected with 300 ng of the wild type or mutant VP16-(SMRT-BBD) plasmids. Panel E is a graph showing experimental results where 50 ng of bait GAL4-PLZF (full-length) plasmid was transfected alone or in combination with 200 ng of prey plasmid expressing

15 VP16-full-length SMRT wild type or point mutants (Top), or 50 ng of bait GAL4-PLZF plasmid was transfected alone or in combination with 200 or 600 ng of prey plasmid expressing VP16-(SMRT-BBD) (Bottom). Panels F-N shows confocal laser scanning microscopy sections collected from 293 T cells cotransfected with a plasmid expressing full length BCL6 along with plasmids

20 expressing wild type (WT) or mutant (AA, IS) VP16-(SMRT-BBD) domain fusions. Immunolocalization was performed using BCL6 monoclonal antibodies with Cy2 secondaries (F,I,L), and VP16 polyclonal antibodies with Cy3 secondaries (G,J,M). The overlays of the BCL6 and VP16(SMRT-BBD) images are shown in panels H,K,N.

25 FIG. 6 shows graphs and a photograph showing that the BCL6 BTB/SMRT-BBD interaction is critical for corepressor function. Results are shown as fold repression compared to the relative luciferase units of the empty vector control. Panel A is a graph showing transcriptional repression activity of GAL4-BTB<sup>BCL6</sup> fusions transfected with a (GAL4)<sub>5</sub>-TK-Luc reporter construct. Panel B is a graph showing results from reporter assays performed

with either full length wild-type BCL6 or full length BCL6 with the N21K/H116A point mutations. The reporter construct ((BCL6)<sub>4</sub>-TK-LUC) contains four BCL6 binding sites. Panel C is a graph showing corepression of GAL4-BTB<sup>BCL6</sup> fusions with full-length SMRT. Panel D is a graph showing corepression of

5 GAL4-BTB<sup>BCL6</sup> fusions with full-length BCoR. Panel E is a graph showing the corepression effect of full-length SMRT with full length BCL6. Panel F shows BCL6 immunoblots of 293T cells transfected with 100 ng of wild-type and mutant full-length BCL6 plasmids. Immunoblots verifying the expression of the GAL4-BTB<sup>BCL6</sup> fusion proteins are shown in FIG. 5C.

10 FIG. 7 is diagrams, photographs and micrographs demonstrating that CoR motif peptides bind to Bcl-6 and block recruitment of SMRT. Panel A shows a 1.3 Å resolution image of the Bcl-6 BTB dimer-SMRT CoR motif complex. The surface of the dimer is shown in white and the peptide backbone of each monomer is shown in red and blue respectively. Two CoR motif sequences (yellow and green) bind simultaneously to the BTB dimer. Panel B shows the amino acid sequence of the WP and MP CoR motif peptides. Panel C shows immunoblots of whole cell lysates (WCL), cytoplasm (CF) and nuclear extract (NE) 293T and Ly1 cells with HA antibodies after a one hour exposure to PB, WP or MP. Panel D shows immunoblots of an *in vitro* co-

15 immunoprecipitation of endogenous Bcl-6 with CoR motif peptides. Ly1 NE exposed to PB, WP or MP (0,12 mg/ml) were precipitated with Bcl-6 monoclonal antibodies or normal mouse serum (NMS) and immunoblotted with HA antibody. Panel E shows immunoblots of *in vivo* co-immunoprecipitations of Bcl-6 and CoR motif peptides. Ly1 and 293T cells transiently transfected with

20 Bcl-6 were exposed to PB or 1μM WP or MP for 1 hour. Immunoprecipitations and immunoblotting were performed on these lysates as in panel D. Panel F shows immunoblots of *in vitro* co-immunoprecipitations of PLZF and CoR motif peptides. NE of 293T cells transiently transfected with PLZF were exposed to PB or 1μM WP or MP for 1 hour. PLZF was immunoprecipitated, and

25 Panel G shows immunoblots of *in*

vivo co-immunoprecipitations between BCL6 and SMRT. 293T cells were co-transfected with BCL6 and SMRT and exposed to PB or 1  $\mu$ M WP or MP for 1 hour. Lysates were subjected to immunoprecipitation with BCL6 rabbit polyclonal antibodies or normal rabbit serum (NRS) and immunoblotted with 5 SMRT polyclonal antibodies. Lysate input expression of SMRT and Bcl-6 and actin loading controls are also shown. Panel H shows immunofluorescence confocal micrographs of BCL6, SMRT, and CoR Motif peptides. 293T cells were co-transfected with BCL6 and SMRT and after 24 hours were exposed to PB or 1  $\mu$ M WP or MP for one hour. Immunostaining was performed using mouse Bcl-6 10 with and rabbit HA or SMRT and secondary antibodies conjugated with Cy2 (BCL6) or Cy3 (HA or SMRT), followed by DAPI staining, and visualized by laser confocal scanning microscopy. The type of treatment (PB, WP or MP) is indicated to the left of each row of images.

FIG. 8 is graphs demonstrating that lateral groove corepressor blockade is 15 specific for BCL6 and is required for transcriptional repression of natural and endogenous target genes. Panels A - E shows results of reporter assays performed in 293T cells transfected with constructs as indicated and TK-renilla as internal control. In all cases, after 24 hours cells were exposed to PB (white bars), or 1  $\mu$ M WP (gray bars) or MP (black bars) for 20 hrs and harvested for 20 dual luciferase assays. Fold repression is calculated compared to BCL6. Fold repression was calculated relative to vector control for each experiment. Transfections were performed in 24-well dishes as follows: Panel A: 50 ng of 25 GAL4<sup>1-147</sup> or GAL4-BCL6<sup>BTB</sup> with 50 ng (GAL4)<sub>5</sub>-TK-Luc reporter; Panel B: 50 ng of GAL4<sup>1-147</sup> or GAL4-HIC1<sup>BTB</sup> with 50 ng (GAL4)<sub>5</sub>-TK-Luc reporter; Panel C: 200 ng GAL4<sup>1-147</sup> or GAL-PLZF<sup>BTB</sup> with 50 ng (GAL4)<sub>5</sub>-TK-Luc reporter; Panel D: 50 ng of pEF vector or full length pEF-Bcl-6 with 50 ng (Bcl-6)<sub>3</sub>-TK-Luc reporter; Panel E: 50 ng of pEF vector or full length pEF-Bcl-6 with 50 ng (Bcl-6)<sub>3</sub>-TK-Luc reporter alone or with 200 ng of CMX-SMRT or 200 ng pEF-BCoR. Panel F shows the results of real time PCR detection of mRNA of the endogenous Bcl-6 30 target genes cyclinD2, CD80, CD69 Bcl-6, performed in Ly1 and LY8 cells,

treated with PB (white bars), or 1  $\mu$ M WP (gray bars) or MP (black bars) for 7 hours.

FIG. 9 is photographs of experimental results demonstrating that lateral groove blockade alters BCL6 target promoter repressosome composition and chromatin structure without disrupting DNA binding by BCL6. Panel A shows the results of electrophoretic mobility shift assays performed using nuclear extracts prepared from 293T cells transfected with full length BCL6. In each case 2  $\mu$ g of nuclear extract was allowed to interact with 10 fmol  $^{32}$ P labeled oligonucleotides probes containing a canonical BCL6 DNA binding site. In addition, reactions were exposed to 50-fold excess unlabeled probe in lanes 2,9,10,11,12; 0.2  $\mu$ g Bcl-6 antibody and in lanes 3,13,14, 0.1  $\mu$ g serum, 5  $\mu$ g WP in lanes 5,9,13,15; 1  $\mu$ g WP in lanes 6,10,14,16; 5  $\mu$ g MP in lanes 7,11; 1  $\mu$ g MP in lanes 8,12; "X" denotes probe alone in lane 17. White arrow: high molecular weight BCL6 mobility shift. Black arrow: lower molecular weight BCL6 mobility shift in the presence of WP. Panel B shows the results of chromatin immunoprecipitations (ChIP) performed in Ly1 cells treated for 7 hrs with 1  $\mu$ M of MP or WP. Cross-linked chromatin was precipitated with BCL6, N-CoR, SMRT or HA polyclonal antibodies or normal rabbit serum (NRS). The resulting purified DNA fragments and 5% input were amplified by end-point PCR using primers surrounding the Bcl-6 binding site on the MIP-1 $\alpha$  promoter. Panel C shows the results of ChIP assays where Ly1 cells were treated as above, but precipitated with histone 3, lysine 9-dimethyl (H3K9-met) or histone 4 pan-acetylated (H4-Ac) polyclonal antibodies or NRS. The resulting purified DNA fragments and 5% input were amplified by end-point PCR using primers surrounding the BCL6 binding site on the MIP-1 $\alpha$  promoter. Panel D shows the results of real time PCR detection of mRNA of the endogenous Bcl-6 target gene MIP1 $\alpha$ , performed in Ly1 cells treated with PB (white bars) or 1  $\mu$ M WP (gray bars) or MP (black bars) for 7 hours.

FIG. 10 is graphs and diagrams demonstrating that BCL6 lateral groove blockade causes apoptosis and cell cycle arrest of BCL6 dependent human B-cell

lymphoma cells. Panels A-D shows the results of experiments where a group of cells including Ly1, Ly4, Ly7, Ly8, Ly10, Ly12, Raji, Daudi and U937 were exposed to PB or 1 mM WP or MP for 48 hours and evaluated as follows: Panel A: cell viability was determined by performing XTT assays. The results are expressed relative to the viability of cells exposed to buffer alone (which is equivalent to untreated cells); Panel B: apoptosis was determined by FACS counting of fixed cells and stained with propidium iodide. The fraction of apoptotic hypodiploid DNA content (Pre-G1/G0) cells is indicated in each graph; Panel C: Differentiation was determined by staining treated cells with antibodies for the CD10 (germinal center) and CD38 (plasmacytic) surface antigens and performing flow cytometry as indicated; Panel D: Cell cycle progression was determined by fixing and staining cells with propidium iodide and determining DNA content by FACS. Cell cycle analysis was performed using MotFit software.

15    **Detailed Description of the Invention**

The present invention is based on the identification of the BCL6 site of corepressor binding, and the discovery that peptides having the sequence of the corepressor binding site inhibit corepressor binding to BCL6. This inhibition causes apoptosis of B-cell lymphoma cells expressing BCL6. See Examples 1 and 2.

Thus, in some embodiments, the invention is directed to compounds that bind to the BCL6 lateral groove and prevent corepressor binding. Based on the work described in Examples 1 and 2, the skilled artisan could design many such compounds. These embodiments are not narrowly limited to any particular compound, and the compound can be, for example, an organic molecule less than 1000 MW, or an aptamer, both of which can be designed or identified by known methods. In preferred embodiments, the compound is a peptide or mimetic. These peptides or mimetics preferably comprise the sequence eipx, where x is a basic amino acid or analog.

As used herein, “mimetics” includes any of the many known compounds that behave like peptides, but are made of amino acid analogs that are more resistant to degradation than peptides.

Numerous examples of the invention peptides or mimetics can be

5 identified by comparing the sequences of the BCL6 lateral groove binding sites from the SMRT, N-CoR, and BCoR corepressors, provided herein as SEQ ID NO:s 1-9 (see Appendix for identification of each sequence). The 17mers identified as SEQ ID NO:s 1-3 is the minimum sequence to achieve maximal inhibition of corepressor binding, but larger sequences, including 84mers, or

10 longer, are also effective.

It is noted in a comparison of SEQ ID NO:1-3, that the sequences derived from SMRT (SEQ ID NO:1) and N-CoR (SEQ ID NO:2) are extensively homologous, and the differences between them generally comprise a conservative substitution. Although the sequence derived from BCoR (SEQ ID NO:3) varies from the SMRT and N-CoR sequences, the differences between the BCoR sequence aligned with the SMRT and N-CoR sequences are also conservative, especially around the invariant eip motif. In particular, the sequence eipx, where x is a basic amino acid or analog (for example, k or r) appears to be crucial. Thus, the skilled artisan could identify numerous peptide sequences that would bind to the BCL6 lateral groove and inhibit corepressor binding, simply by aligning the residues of the three corepressor sequences (SEQ ID NO:1-3) and identifying sequences that combine the aligned residues, or providing conservative substitutions to the amino acids or analogs.

20 Preferably, the peptide or mimetic comprises the sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.

The peptides or mimetics can comprise any number of amino acids or analogs as the lateral groove binding moiety, up to 84 or more, including 28 or less, 21 or less, or the minimal 17 amino acid or analog residues. The peptide or mimetic can even include the entire corepressor (i.e., SMRT, BCoR or N-CoR)

sequence, where the sequence is mutated to prevent the peptide or mimetic from functioning as a corepressor.

The peptide or mimetic can also comprise one or more functional groups, such as a moiety that facilitates purification, e.g., a (His)<sub>6</sub> moiety or an antibody-binding epitope. Another functional group that can be utilized as part of the peptide or mimetic is a moiety that facilitates entry of the peptide or mimetic into a cell, such as the protein transduction domain from the HIV pTAT protein. An additional useful functional group here is a moiety that facilitates detection of the peptide or mimetic, such as a fluorescent moiety, a radioactive moiety, or an antigen. As a preferred example of a useful peptide comprising functional moieties, see the peptide WP, described in Example 2, which consists of the 21mer having the sequence of SEQ ID NO:4, along with a (His)<sub>6</sub> moiety, the protein transduction domain from the HIV pTAT protein, and a hemagglutinin epitope tag for immunodetection of the peptide.

For therapeutic uses, the peptide or mimetic is preferably in a pharmaceutically acceptable excipient. Such compositions can be formulated without undue experimentation for administration to a mammal, including humans, as appropriate for the particular application. Additionally, proper dosages of the compositions can be determined without undue experimentation using standard dose-response protocols.

Accordingly, the peptide or mimetic compositions designed for oral, lingual, sublingual, buccal and intrabuccal administration can be made without undue experimentation by means well known in the art, for example with an inert diluent or with an edible carrier. The compositions may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the pharmaceutical compositions of the present invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like.

Tablets, pills, capsules, troches and the like may also contain binders, recipients, disintegrating agent, lubricants, sweetening agents, and flavoring

agents. Some examples of binders include microcrystalline cellulose, gum tragacanth or gelatin. Examples of excipients include starch or lactose. Some examples of disintegrating agents include alginic acid, corn starch and the like. Examples of lubricants include magnesium stearate or potassium stearate. An 5 example of a glidant is colloidal silicon dioxide. Some examples of sweetening agents include sucrose, saccharin and the like. Examples of flavoring agents include peppermint, methyl salicylate, orange flavoring and the like. Materials used in preparing these various compositions should be pharmaceutically pure and nontoxic in the amounts used.

10 The peptide or mimetic compositions of the present invention can easily be administered parenterally such as for example, by intravenous, intramuscular, intrathecal or subcutaneous injection. Parenteral administration can be accomplished by incorporating the compositions of the present invention into a solution or suspension. Such solutions or suspensions may also include 15 sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents. Parenteral formulations may also include antibacterial agents such as for example, benzyl alcohol or methyl parabens, antioxidants such as for example, ascorbic acid or sodium bisulfite and chelating agents such as EDTA. Buffers 20 such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose may also be added. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.

Rectal administration includes administering the pharmaceutical peptide 25 or mimetic compositions into the rectum or large intestine. This can be accomplished using suppositories or enemas. Suppository formulations can easily be made by methods known in the art. For example, suppository formulations can be prepared by heating glycerin to about 120° C., dissolving the composition in the glycerin, mixing the heated glycerin after which purified 30 water may be added, and pouring the hot mixture into a suppository mold.

Transdermal administration includes percutaneous absorption of the composition through the skin. Transdermal formulations include patches (such as the well-known nicotine patch), ointments, creams, gels, salves and the like.

The present invention includes nasally administering to the mammal a 5 therapeutically effective amount of the composition. As used herein, nasally administering or nasal administration includes administering the composition to the mucous membranes of the nasal passage or nasal cavity of the patient. As used herein, pharmaceutical compositions for nasal administration of a composition include therapeutically effective amounts of the composition 10 prepared by well-known methods to be administered, for example, as a nasal spray, nasal drop, suspension, gel, ointment, cream or powder. Administration of the peptide or mimetic composition may also take place using a nasal tampon or nasal sponge.

In additional embodiments, the invention is directed to methods of 15 blocking corepressor binding to a BCL6 lateral groove. The methods comprise contacting the BCL6 with any of the compounds described above.

In preferred embodiments of these methods, the BCL6 is in a mammalian cell, preferably a cancer cell that requires BCL6 repression. Addition of the peptides to such cells cause apoptosis in a significant percentage of the cells 20 (Example 2).

It is preferred that cancer cells treated in these methods are in a living mammal. The invention methods would be expected to work in any mammal, however, in the most preferred embodiments, the mammal is a human.

Additionally, it is preferred that the cancer cell in these embodiments is a 25 lymphoma cell or breast cancer cell, since those forms of breast cancer often require BCL6 repression to avoid apoptosis.

It is preferred in these methods that the compound comprises a peptide or mimetic that comprises the sequence of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3.

In other embodiments, the invention is directed to methods of inhibiting BCL6 repression in a mammalian cell. The methods comprise treating the cell with any of the above-described compounds. As with the methods described above, the cell is preferably a cancer cell, most preferably a lymphoma or a 5 breast cancer cell. It is also preferred that the cell is in a mammal, most preferably a human. It is also preferred that the compound comprises a peptide or mimetic having the sequence of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3.

In related embodiments, the invention is directed to methods of treating a mammal with cancer. The methods comprise administering any of the above 10 described compounds, in a pharmaceutically acceptable excipient, to the mammal. In these methods, the cancer requires BCL6 repression. As such, treatment with the peptide prevents corepressor binding and causes apoptosis of the cell.

In preferred embodiments, the mammal is a human; it is also preferred 15 that the cancer is a lymphoma or a breast cancer. As with the methods described above, the preferred compound comprises a peptide or mimetic comprising the sequence of SEQ ID NO:1, SEQ ID NO:2. or SEQ ID NO:3.

The invention is additionally directed to methods of identifying a compound that inhibits corepressor binding to BCL6. The methods comprise 20 identifying a compound that binds to a BCL6 lateral groove, where such compounds would inhibit corepressor binding. In these methods, the compound can be identified by any known method that utilizes the BCL6 lateral groove structural information provided in Examples 1 and 2.

These methods can employ a library screening protocol, i.e., where a 25 library of compounds is screened for lateral groove binding. Preferably, however, the methods utilize the structure of the BCL6 lateral groove to aid in the design of a molecule that would be expected to bind to the BCL6 lateral groove and inhibit corepressor binding.

The skilled artisan could design the particular format for these methods 30 by utilizing known procedures, For examples, the methods could employ an *in*

*vitro* or an *in vivo* procedure (i.e., in cell culture), as utilized in Examples 1 or 2.

These methods are not limited to the compound that could be tested. The compound can, e.g., be an organic compound less than 1000 molecular weight. Alternatively, the compound can be an aptamer. In preferred embodiments, the compound is a peptide or mimetic.

Preferred embodiments of the invention are described in the following examples. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims which follow the examples.

Example 1. Mechanism of SMRT Corepressor Recruitment by the BCL6 BTB  
15 Domain

Example Summary

*BCL6* encodes a transcription factor that represses genes necessary for the terminal differentiation of lymphocytes within germinal centers, and the misregulated expression of this factor is strongly implicated in several types of B-cell lymphoma. The homodimeric BTB domain of *BCL6* (also known as the POZ domain) is required for the repression activity of the protein, and interacts directly with the SMRT and N-CoR corepressors that are found within large multi-protein histone deacetylase-containing complexes. We have identified a 17 residue fragment from SMRT that binds to the *BCL6* BTB domain, and determined the crystal structure of the complex to 2.2 Å. Two SMRT fragments bind symmetrically to the *BCL6* BTB homodimer and, in combination with biochemical and *in vivo* data, the structure provides insight into the basis of transcriptional repression by this critical B-cell lymphoma protein.

### Introduction

Given the important role of BCL6 in cellular differentiation and oncogenesis, we performed an in depth structural analysis to determine the mechanism through which BCL6 recruits the corepressors needed to mediate its silencing effects.

### 5 Results

**BCL6 BTB domain structure.** We crystallized the BTB domain from BCL6 under two different conditions (form I and form II) and solved its structure in the two distinct packing environments to 1.3 Å and 2.2 Å, respectively (Table 1 and FIG. 1). It was necessary to mutate three non-conserved cysteines to 10 prevent aggregation of the recombinant protein (C8Q/C67R/C84N). This mutated BCL6 BTB domain had essentially the same activity as the wild-type protein in transcriptional repression assays (FIG. 1C). In all of the following sections, the *in vitro* experiments involving purified BCL6 BTB domain were done on the form with the three substituted cysteines, while all cellular assays 15 were done in the wild-type background.

Table 1: Crystallographic statistics

	Form I (seMet)			Form I (native)	Form II	Complex
5	Resolution (Å)	2.10	2.10	2.10	1.30	2.20
	Wavelength (Å)	0.97947	0.97925	0.95742	0.8980	1.54
	Unique Reflections	6586	6600	6719	27157	10909
	Redundancy	7.1	7.2	7.2	3.7	3.4
	Completeness %	96.2 (73.8)	96.4 (74.8)	98.2 (87.8)	95.7 (93.7)	95.0 (85.3)
	$\langle   > / \langle \sigma   >$	21.7 (6.2)	21.7 (7.5)	24.7 (9.1)	24.4 (4.3)	12.8 (3.2)
	Rsym (%)	9.3 (23.3)	8.7 (20.6)	6.8 (17.7)	5.1 (30.2)	9.2 (28.1)

	Refinement	Form I (native)	Form II	Complex
10	Resolution (Å)	30.0 - 1.30	30.0 - 2.20	30.0 - 2.20
	Space group	C2	C2	P2 <sub>1</sub>
	Unit cell	30.61	140.75	54.23
	a (Å)	71.85	32.66	38.54
	b (Å)	55.41	48.63	76.66
	c (Å)	105.9	94.73	92.92
	$\beta$ (°)	0	0	0
15	Data cutoff F/σ(F)	12.83 / 17.30	20.0 / 24.97	22.66 / 26.77
	R / R <sub>free, 5%</sub> (%)	0.0130	0.0095	0.0097
	RMSD bond lengths (Å)	1.53	1.40	1.40
	RMSD bond angles (°)			
	Number of atoms / residues			
	BTB <sup>BCL6</sup>	1000 / 122	1972 / 244	2002 / 248
	SMRT-BBD	0	0	274 / 36
20	Waters	188	130	132

25 Numbers in parentheses refer to the high resolution shell (2.18-2.10 Å for Form I SeMet, 1.35-1.30 Å for Form I native, 2.28-2.20 Å for Form II and 2.28-2.20 Å for Complex).

As expected, the BCL6 BTB domain is structurally homologous to the PLZF BTB domain (Ahmad et al., 1998; Li et al., 1999), and forms a tightly interwound butterfly-shaped homodimer with an extensive hydrophobic interface. A least squares superposition of the crystallographically unique 5 chains of the BCL6 BTB structures reported in this study with the BTB domain of PLZF (Ahmad et al., 1998) reveals virtually identical structures, with an average pairwise RMSD value of 1.0 Å for equivalent C $\alpha$  atoms (FIG. 1B). The N-terminus of each chain is associated with the main body of the partner chain, generating a two-stranded antiparallel  $\beta$ -sheet between  $\beta$ 1 of one monomer and 10 strand  $\beta$ 5' of the other. The domain is an obligate homodimer, with no evidence of exchange between subunits (KFA and GGP, unpublished observations).

The principle dimer contacts between the BCL6 BTB subunits are mediated by  $\beta$ 1, 1,  $\alpha$ 2,  $\beta$ 5 and  $\alpha$ 6. Prominent surface features of the dimer include a conserved groove formed by the two  $\alpha$ 3/ $\beta$ 4 loops at the “top” of the 15 dimer, and an extensive hydrophobic concave surface formed by  $\beta$ 1/ $\alpha$ 6'/ $\beta$ 1'/ $\alpha$ 6 on the distal “bottom” side of the dimer.

Residues 1414-1430 of SMRT interact with the BCL6 BTB domain. The highly related corepressors N-CoR and SMRT (also known as N-CoR II) have an overall pairwise sequence identity of 45%, and large segments of these proteins 20 are predicted to be intrinsically disordered. We have previously demonstrated the direct binding of murine N-CoR (residues 1351-1616) and human SMRT (residues 1414-1498) to the BCL6 BTB domain (Melnick et al., 2002). A shorter SMRT fragment from positions 1414 to 1441 binds to the BCL6 BTB domain with similar affinity (data not shown), and we used this as a basis for 25 determining the minimal interaction fragment in SMRT. A series of N and C terminal deletions were made to SMRT<sup>1414-1441</sup> and the binding of these fragments to the BCL6 BTB domain was assessed in a co-purification assay in which the corepressor peptides were expressed as fusion proteins with histidine-tagged thioredoxin (Trx) (FIG. 2A,B).

Surface plasmon resonance (SPR) biosensor measurements were used to measure the relative strengths of interactions between the corepressor fragments and the BCL6 BTB domain (FIG. 2C,D). We measured a dissociation constant of  $15.8 \pm 3$  nM for the interaction of SMRT<sup>1414-1441</sup> and the BCL6 BTB domain (FIG. 2C), and interestingly, a 2.5-fold stronger affinity of the BTB domain for the equivalent N-CoR<sup>1351-1383</sup> peptide (FIG. 2D). The relative binding affinities of the truncated and mutant SMRT peptides were largely in agreement with the copurification results, however, the SPR analysis revealed slightly weaker binding by SMRT<sup>1417-1441</sup> relative to SMRT<sup>1414-1441</sup>, suggesting that residues 1414-1416 make a small but significant contribution to the overall strength of the interaction. We observed stronger binding of SMRT<sup>1414-1430</sup> relative to the two longer SMRT peptides, and this may be due to the presence of a free C-terminal carboxyl group in this fragment. From this analysis, the minimal fragment in SMRT required for interaction with the BCL6 BTB domain ranges from residues Leu-1414 to Arg-1430, and we used this fragment for further studies. We refer to this segment of the SMRT/N-CoR corepressors as the BCL6 binding domain (BBD).

We compared the measured dissociation constant from SPR with the value obtained in solution by isothermal titration calorimetry (ITC) (FIG. 2E). In solution, SMRT<sup>1414-1430</sup> (SMRT-BBD) binds to the BCL6 BTB domain with a  $K_d$  of  $11.4 \pm 1$   $\mu$ M, a value considerably less than from the SPR measurements. The stoichiometry of the interaction by ITC is  $1.11 \pm 0.06$  SMRT peptides per BCL6 chain, and since the BTB domain is an obligate homodimer, these results indicate that two peptides bind per protein dimer. There is no indication of cooperativity. The ITC measurements reveal a favorable enthalpic contribution ( $\Delta H = -23.2 \pm 1.6$  kcal/mol) and an unfavorable entropic contribution ( $-T\Delta S = 16.4 \pm 2.3$ ) to the free energy of the interaction.

A micromolar dissociation constant is similar to the affinity observed for SH3 (Kay et al., 2000), WW (Sudol et al., 2001) and EVH1 (Ball et al., 2002) domains and their respective peptide binding partners. The stronger association

as measured by SPR may be due to the fact that solid-phase techniques often overestimate binding affinities, and differences with solution phase measurements are often attributed to favorable avidity effects when one component is immobilized (Ladbury et al., 1995). Thus, for example, the 5 affinities of the NHERF PDZ1 domain with carboxy-terminal peptides are typically in the nanomolar range when measured with SPR or cellular systems, but are found to be in the micromolar range when measured in homogenous solutions by techniques such as fluorescence polarization or ITC (Hamilton et al., 2003). We expect that avidity effects are important in this system because 10 of the bivalent nature of the BCL6 BTB domain / BBD interaction.

We failed to measure any interaction between the PLZF BTB domain and any of the SMRT or N-CoR fragments by either the co-purification assay, SPR or ITC. We previously showed that the interaction of the PLZF BTB domain with the SMRT and N-CoR fragments was at the limit of detectability by the 15 co-purification assay (Melnick et al., 2002), and with improvements to the method, we now conclude that any associations between these peptides and the PLZF BTB domain are not measurable by these techniques.

Structure of the BCL6 BTB Domain / SMRT-BBD Complex. The human BCL6 BTB domain was co-crystallized with the SMRT-BBD peptide in a form 20 with an entire BTB dimer and two SMRT peptides in the asymmetric unit. Two SMRT-BBD chains associate with the BCL6 BTB dimer in the complex, resulting in an overall 2:2 binding ratio (Table 1, FIGS. 3 and 4). Each corepressor fragment binds in an extended conformation along a shallow groove formed at the BTB dimer interface, making extensive contacts with both chains of the BTB 25 dimer and burying approximately 1080 Å<sup>2</sup> of surface area per peptide.

Although circular dichroism (CD) spectroscopy indicates that the unliganded SMRT fragment is unstructured in solution, the peptide in the complex is well defined and adopts a fixed conformation. The two crystallographically unique SMRT chains are virtually identical, and superpose with a Ca RMSD of 0.65 Å 30 (FIG. 4E) and have very similar side chain conformations. There are no

SMRT/SMRT contacts, and we describe the interactions of only one of the two corepressor chains with the BTB domain (the yellow chain in FIGS. 3 and 4), as essentially all the interactions are conserved across each of the two SMRT/BTB dimer interfaces.

5 There are only minor adjustments to the BCL6 BTB domain side chains upon complex formation, most notably in residues Arg-13, Arg-24, and His-116. In the unliganded structures, these amino acids have significantly higher side chain temperature factors relative to their neighboring residues. These adopt multiple conformations across the form I and form II crystals, and some of these  
10 conformers partially block the ligand binding groove. However, in the SMRT complex, these three residues are well-structured and make some of the more important ligand contacts (FIG. 3E). For example, in order to accommodate the SMRT fragment, Arg-13 swings out of the ligand binding groove, forms a hydrogen bond with Asp-17 from the same BCL6 chain, and makes numerous  
15 polar and non-polar contacts with the peptide.

The main chain torsion angles of the corepressor peptide all lie within the  $\beta$ -strand region of the Ramachandran plot, with the exception of Gly-1422 and Ser-1424, which are in the  $\alpha$ -helical region. This causes a kink in the middle of the peptide, allowing the C-terminal half of the fragment to run up the front of  
20 the BTB dimer. Residues from both BTB chains contact each of the SMRT peptides, with contributions mainly from  $\beta 1'$  and  $\alpha 1'$  from one BCL6 BTB chain, and  $\alpha 2$ ,  $\alpha 3$  and  $\alpha 6$  from the other. The peptide binding interface is mostly polar, and the majority of protein-peptide interactions are mediated through backbone and sidechain hydrogen bonds, as well as through water-mediated  
25 hydrogen bonds. Both sites contain six bridging waters that contact both the peptide and the BTB domain (FIG. 4E), and three of these waters are also found in the unliganded BCL6 BTB crystals.

The N-terminal portion of each SMRT peptide interacts in parallel with BCL6  $\beta 1$ , and adds an additional  $\beta$ -strand to the existing  $\beta 1/\beta 5'$  sheets at the  
30 bottom of the dimer (FIGS. 3 and 4D). The majority of the interactions in this

region are mediated by main-chain hydrogen bonds between the peptide and the amino terminus of one of the BCL6 BTB chains. The relevance of these interactions is supported by the binding data, as SMRT residues 1414-1416 make only minor contributions to the strength of the interaction, while the 5 deletion of residues 1414-1420 abrogates complex formation altogether (FIG. 2).

In the middle region of the peptide (FIG. 4C), SMRT residues Ser-1424 and Ile-1425 are deeply buried in the complex, and are found in a groove in the BCL6 BTB domain bounded by Arg-13' ( $\alpha 1'$ ) and His-116 ( $\alpha 6$ ). Ser-1424 makes 10 three hydrogen bond interactions to the BCL6 BTB domain, and Ile-1425 points in towards a hydrophobic pocket formed in part by Val-18 ( $\alpha 1'$ ) and Cys 53 ( $\alpha 2$ ). As expected, the SI to IS mutation abrogates binding of the SMRT-BBD to the BCL6 BTB domain (FIG. 2), indicating that these residues make critical contributions to complex stability. Surprisingly, BCL6 residues Arg-13 and His- 15 116 make some of the largest contributions to the buried interface surface in the complex, yet they are not conserved within the BTB domain family (FIG. 3E).

A network of polar and non-polar interactions between the C-terminal end of the SMRT peptide and the second half of helix  $\alpha 1$  also contribute to the overall stability of the complex (FIG. 4D), although the contacts in this region 20 are not as extensive as in other parts of the interface. This region is nonetheless required for binding, since replacing residues 1427-1430 of SMRT-BBD with alanines (EIPR->AAAA) abolished the binding as measured by SPR and the copurification assay (FIG. 2). Of these four residues, Ile-1428 makes the most contacts with the dimer.

25 Mutations in the BCL6 BTB domain abrogate the interaction with SMRT-BBD. To further validate the interaction, we mutated BCL6 residues that contact the SMRT peptide. The H116A mutation has a significantly reduced affinity for Trx-(SMRT-BBD), while the N21K mutation showed no binding at all (FIG. 4F). The latter mutant was chosen to introduce the equivalent residue 30 from PLZF into BCL6 (FIG. 3E), and was predicted to be incompatible with

SMRT binding based on the observed structure of the complex. The H116A and N21K mutants were well expressed as soluble proteins in *E. coli*, and the purified proteins eluted as single peaks by gel filtration chromatography at similar elution volumes as the native protein. In addition, the two mutant 5 proteins had nearly equivalent CD spectra as the wild type protein, and all three proteins had similar thermal denaturation midpoint transition temperatures (60.2°, 63.1° and 61.0° for the wt, H116A and N21K mutants, respectively). Thus, any differences in the biochemical and biological activity of these mutants are most likely due to changes in the protein-protein interaction properties of 10 the domain, and not due to non-specific effects such as defects in folding (Melnick et al., 2000).

SMRT BBD interacts with the BTB domain of BCL6 but not PLZF *in vivo*.

We next tested whether the interaction of the SMRT-BBD with the BCL6 BTB domain occurred in a similar manner *in vivo* in mammalian two-hybrid assays. 15 Previous work showed that the interaction of the BCL6 BTB domain with SMRT can be detected in such experiments (Huynh and Bardwell, 1998; Melnick et al., 2002). GAL4-BTB<sup>BCL6</sup> was co-expressed and allowed to interact with wild-type or mutant VP16-(SMRT-BBD) peptide fusions with substitutions at the critical Ser-1424 and Ile-1425 positions (FIG. 5A). In the absence of the SMRT prey, 20 GAL4-BTB<sup>BCL6</sup> repressed transcription from the (GAL4)<sub>5</sub>-TK-Luc containing reporter construct. When VP16-(SMRT-BBD) was co-transfected with GAL4-BTB<sup>BCL6</sup>, the transcriptional response switched from repression to activation, indicating that the two proteins interact. In contrast, both SMRT mutants were unable to mediate activation, indicating weak or no binding to the BTB domain 25 of BCL6. We next performed reciprocal experiments in which GAL4-BTB<sup>BCL6</sup> wildtype and mutant fusion proteins was used as the bait to capture VP16 activation domain fusions with full-length SMRT (FIG. 5B). The N21K, H116A and N21K/H116A BTB mutants gave background signals indicating no interaction, while the wild-type BCL6 BTB domain produced an activation signal

in this assay, indicating that the two proteins interact. Equivalent expression levels of the constructs were verified by immunoblotting (FIG 5C and D).

We previously reported that the interaction between the PLZF BTB domain and SMRT was undetectable by mammalian two-hybrid assays (Melnick et al., 2002). However, a full-length PLZF GAL4 fusion was able to generate a mammalian two-hybrid signal when co-expressed with full-length VP16-SMRT (FIG. 5E). The interaction was unaffected when SMRT residues 1424 and 1425 were mutated to either AA or IS. In addition, no interaction was observed when VP16-(SMRT-BBD) was used as the PLZF prey. Therefore, the interaction of the SMRT BBD motif described here is specific for BCL6 and not PLZF both *in vivo* and *in vitro*. Interestingly, the BCL6 BTB domain is a much more potent transcriptional repressor than the PLZF BTB domain when equivalent amounts of GAL4-BTB expression plasmid are used in reporter assay (FIG. 1C), correlating with the significantly greater *in vitro* and *in vivo* affinity for SMRT.

**BCL6 binding to SMRT-BBD directs localization to nuclear speckles.**

BCL6 normally localizes to nuclear speckles in a BTB-dependent manner (Dhordain et al., 1995). Furthermore, BCL6 and SMRT colocalize in nuclear speckles when overexpressed in transfected cells (Huynh and Bardwell, 1998). Full-length BCL6 could recruit VP16-(SMRT-BBD) to nuclear speckles, while the VP16-(SMRT-BBD<sup>SI->AA</sup>) and VP16-(SMRT-BBD<sup>SI->IS</sup>) mutants showed virtually no spatial overlap with BCL6 (Figure 5F-N). The BBD motif is therefore sufficient to direct recruitment to BCL6 nuclear speckles *in vivo*.

**The BTB lateral groove is required for BCL6 transcriptional repression.**

Since the BCL6 lateral groove appears to be the major binding site for BBD containing corepressors, we tested whether this contact was required for transcriptional repression by the BCL6 BTB domain. GAL4-BTB<sup>BCL6</sup> wild-type or mutant constructs containing the N21K, H116A or N21K/H116A point mutation(s) were co-transfected with a (GAL4)5-TK-Luc reporter. In contrast to wild-type BCL6 BTB, these mutants were completely unable to repress transcription regardless of the dose of expression plasmid administered,

suggesting that corepressor binding in this site mediates BTB dependent transcriptional repression (FIG. 6A). When these same mutations were introduced into full-length BCL6, repression activity was greatly reduced, though not abrogated, indicating that motifs in other regions of BCL6 may 5 partially compensate for the defect in BTB corepressor recruitment (FIG. 6B) (Lemercier et al., 2002; Zhang et al., 2001).

The BCL6 BTB lateral groove motif is required for functional interaction with corepressors. Functionally, SMRT, N-CoR and BCoR enhance the levels of repression by BCL6 (Dhordain et al., 1997; Huynh and Bardwell, 1998; Huynh 10 et al., 2000). The interactions between the BCL6 BTB domain and SMRT, N-CoR and BCoR are mutually exclusive (Huynh et al., 2000), and these corepressors presumably compete for a common binding site on the BTB domain. BCoR contains the sequence motif EIPK from residues 481-484, which may be related to the EIPR portion of the SMRT-BBD motif described here. Wild-type and 15 mutant GAL4-BTB<sup>BCL6</sup> fusion proteins were co-expressed with corepressors in reporter assays. SMRT and BCoR enhanced wild-type BTB repression by 2-3 fold but did not significantly enhance repression by the mutant BTB domains above control levels, indicating that interactions with the BCL6 BTB lateral groove are required for the effect of these corepressors with the BTB domain of 20 BCL6 (FIG. 6C and D).

Finally, to determine whether the BTB lateral groove was also required for corepression of full length BCL6, we tested whether full-length BCL6 harboring the N21K/H116A mutations could functionally interact with SMRT (FIG. 6E and F). While SMRT enhances repression by wild-type full-length 25 BCL6, the protein containing the N21K/H116A mutations is unaffected by the presence of SMRT. Therefore, the lateral groove of the BCL6 BTB domain is required for both physical and functional interaction between BCL6 and BBD-containing corepressors.

### Discussion

The BTB domain of BCL6 may have two roles: first, the dimerization and possible oligomerization of the domain is an architectural feature necessary for the normal function of the protein. Second, direct interactions with 5 corepressors are required for the BTB-mediated repression effects. The BCL6 BTB dimer can bind two BBD peptides, and in a biological context, avidity effects may be important for the association of a BCL6 to HDAC complexes that contain two or more SMRT, N-CoR and/or BCoR chains.

Previous observations of dimer-dimer associations between the  $\beta 1$  regions 10 of PLZF BTB dimers (Ahmad et al., 1998; Li et al., 1999) support the suggestion that higher-order BTB complexes may be functionally important (Ball et al., 1999). We observe only one such interaction between BCL6 dimers in the form 15 I and form II structures presented here out of three possible. If similar BTB dimer-dimer associations are important for BCL6 *in vivo*, it is likely that the association of the SMRT peptide would disrupt these assemblies. Further study will be required to clarify the role, if any, of these effects.

In addition to SMRT, N-CoR and BCoR, the BCL6 BTB domain has been shown to interact with mSin3A and histone deacetylase 1 (David et al., 1998; Dhordain et al., 1998; Wong and Privalsky, 1998), suggesting that several 20 distinct contacts may occur between a BTB domain transcription factor and the components of large repression complexes. While the BTB lateral groove is the site of binding for the BBD motif, additional proteins may recognize other surface features of the domain. The sequences of BTB domains are very diverse (for example, the PLZF and BCL6 BTB domains share only 28% sequence 25 identity), and it is possible that there are additional protein-protein recognition modes in this domain family. Many other protein interaction domains display a wide range of ligand binding properties (Pawson and Nash, 2003). For example, the PH, PTB and EVH1 domains share a common core fold, yet these bind a large variety of peptide or phospholipids ligands using distinct binding 30 sites distributed across the domain surface (Prehoda et al., 1999). In particular,

the conserved charged groove at the top of the BTB dimer is a possible protein-protein interaction site (Ahmad et al., 1998; Melnick et al., 2000; Melnick et al., 2002).

The specificity of the SMRT-BBD for the BCL6 BTB domain but not the 5 PLZF BTB domain correlates with the relative strengths of the domains as transcriptional repressors (FIG. 1C; Melnick et al., 2002). An examination of the BCL6 residues that contact the SMRT-BBD peptide provides some insight into the large difference in affinity between the two BTB domains. Out of the approximately 30 residues of the BCL6 dimer that are buried upon complex 10 formation with SMRT, only three positions (His-14, Asn-23 and Lys-123) are identical in PLZF, while 7 more positions are similar (FIG. 3E). Furthermore, side-chains that make sizable contributions to the buried interface surface in the complex, such as Arg-13, Asn-21, Arg-24, Arg-28 and His-116, are not 15 conserved between the two proteins. An analysis of the corresponding residues in ZID (Bardwell and Treisman, 1994), another transcriptional repressor that recruits components of the histone deacetylase complex (Huynh and Bardwell, 1998), also indicates that the majority of the residues that make sizable contributions to the BCL6/SMRT-BBD complex are not conserved.

The apparent unique specificity of the BCL6 BTB domain for the BBD 20 motif makes this an attractive system for the design of small molecule inhibitors. Recognition of the corepressor motif is essential for the transcriptional repression activity of BCL6, and compounds that disrupt this interaction have potential as therapeutic agents for BCL6-related B-cell lymphoma. Such 25 inhibitors would release the differentiation block in these lymphocytes in a fashion similar to the use of retinoic acid in t(15:17) acute promyelocytic leukemia (APL) (Costoya and Pandolfi, 2001; Lin et al., 2001; Zelent et al., 2001).

#### Experimental Procedures

Plasmids. Fragments of human BCL6 (codons 5-129), SMRT or N-CoR 30 were subcloned into a modified pET-32 expression vector (Novagen), encoding

a thioredoxin fusion protein containing a 6-His tag, a TEV protease site, a BirA biotinylation recognition motif (Cull and Schatz, 2000) and a thrombin protease site N-terminal to the insert site. The GAL4-BTB<sup>BCL6</sup>, BTB<sup>PLZF</sup> and PLZF mammalian expression vectors, and the (GAL4)<sub>5</sub>-TK-Luc reporter constructs 5 were previously described (Li et al., 1997; Melnick et al., 2002). VP16-full length SMRT fusions, full-length BCL6 expression plasmid, BCoR expression plasmid and BCL6 binding site reporters were a gift of V. Bardwell (University of Minnesota) (Huynh and Bardwell, 1998; Huynh et al., 2000). Point mutations were introduced using the QuikChange reagents and protocols (Stratagene).

10 Protein Expression and Purification. Fusion proteins were expressed in *E. coli* BL21(DE3), and were purified by Ni-NTA affinity chromatography (Qiagen) followed by Superdex-75 chromatography (Pharmacia) in 250 mM NaCl, 20 mM Tris-HCl, pH 8.0. BCL6 BTB domain protein was produced by thrombin digestion of the thioredoxin fusion proteins, and repurified by size-exclusion 15 chromatography in 500 mM NaCl, 20 mM Tris-HCl, 10% glycerol, 1.0 mM TCEP, pH 8.5. Corepressor fusion proteins were biotinylated with BirA and digested with TEV protease to yield peptides for SPR analysis with a biotinylated lysine eight amino acids N-terminal to the first corepressor residue, or digested with thrombin to produce peptides with no additional N-terminal residues for 20 co-crystallization or ITC.

In vitro binding assays. Co-purification: Equimolar amounts of His-tagged thioredoxin-corepressor fusion protein and BCL6 BTB or PLZF BTB domain were combined, incubated for at least two hours, and loaded onto a Ni-NTA spin column (Qiagen). The column was washed three times with 600  $\mu$ l 25 of wash buffer (200 mM NaCl, 20 mM Tris-HCl pH 8.0, 10 mM imidazole), and bound protein was released with 400  $\mu$ l of elution buffer (200 mM NaCl, 20 mM Tris-HCl pH 8.0, 300 mM imidazole). Samples were analyzed on 10-20% SDS-PAGE gels and stained with Coomassie blue.

SPR: Biotinylated corepressor peptides were coupled to streptavidin-30 coated sensor chips to a density of 800 response units (Biacore 2000). BCL6 or

PLZF BTB protein was serially diluted in running buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% v/v surfactant P20) and injected at a flow rate of 5  $\mu$ L/min.

ITC: The binding of SMRT<sup>1414-1430</sup> to BTB domain protein was analyzed on 5 a Microcal VP-ITC instrument at 25 °C. All components were in 150 mM NaCl, 20 mM Hepes pH 7.7, 1 mM TCEP. The experiment consisted of thirty 6.93  $\mu$ L injections of a solution containing 480  $\mu$ M SMRT<sup>1414-1430</sup> into a sample cell containing 1.8 mL of either BCL6 BTB (23.0  $\mu$ M) or PLZF BTB (38.5  $\mu$ M). To correct for dilution and mixing effects, a series of control injections was carried 10 out, in which the heat of dilution was measured in blank titrations by injecting the peptide into the buffer.

Crystallization and Structure Determination. Form I BTB<sup>BCL6</sup>: Crystals were grown at room temperature in hanging drops by mixing 2  $\mu$ L of 8 mg/mL protein with 2  $\mu$ L of reservoir buffer (0.18 M sodium formate and 0.1 M sodium 15 acetate, pH 4.8). A native dataset to 1.3 Å, and three wavelength anomalous diffraction dataset on selenomethionine-substituted protein to 2.1 Å were collected at 100 K at beamline 14D of the Advanced Photon Source (APS). The data were processed with DENZO (Otwinowski and Minor, 1997). SOLVE was used for locating the selenium atoms and initial phasing (Terwilliger and 20 Berendzen, 1999). Initial model refinement was with CNS (Brunger et al., 1998), and later continued with SHELXL-97 (Scheldrick and Schneider, 1997) on the native dataset.

Form II BTB<sup>BCL6</sup>: Crystals were grown at room temperature in hanging drops by mixing 2  $\mu$ L of protein with 2  $\mu$ L of reservoir buffer (30% PEG 8000, 25 0.18 M Sodium Acetate, 0.1 M HEPES pH 7.0). Data were collected at 100 K on a MAR-345 Imaging Plate Detector on a Rigaku RU200 with a copper target. The structure was solved by molecular replacement (CNS) using the form I BCL6 BTB structure, and refined with CNS.

BTB<sup>BCL6</sup>/SMRT<sup>1414-1430</sup> complex: Crystals were grown in hanging drops by 30 mixing 2  $\mu$ L of a protein solution containing 15 mg/mL BCL6 BTB and a 2.5

molar excess of SMRT<sup>1414-1430</sup> with 2  $\mu$ L of reservoir buffer (25% PEG 3350 and 0.2 M ammonium acetate). Data collection, structure solution and refinement were as described for the form II crystals. Molecular graphics in Figures 1, 3 and 4 were generated with PyMol, Molscript and Raster 3D.

5        Mammalian two hybrid assays. Assays were performed in  $5 \times 10^5$  293 T cells plated in 12-well dishes. GAL4 fusion expression “bait” vectors and VP16 “prey” vectors were cotransfected as indicated in the figure legends. Transfections were performed in quadruplicate using the Superfect lipid reagent (Qiagen) and were repeated 4 to 8 times. Cell lysates were subjected to dual 10 luciferase assays (Promega). Equivalent levels of protein expression from the transfected plasmids was verified by immunoblotting with rabbit polyclonal GAL4<sup>1-147</sup> (sc-577) antibodies or mouse monoclonal VP16 (14-5) antibodies (Santa Cruz).

15        Immunofluorescence. 293 T cells were transfected with either 100 ng of pEF-BCL6 or pEF vector control with 200 ng VP16-SMRT constructs or VP16 vector plasmid control. Cells were fixed in ice cold methanol, blocked with 10% donkey serum, permeabilized in 0.1% Tween and then exposed to BCL6 D-8 monoclonal antibody (Santa Cruz) and VP16 polyclonal antibody (Clontech). The cells were exposed to donkey anti-mouse secondary antibodies conjugated 20 to Cy2 and donkey anti-rabbit secondary antibodies conjugated to Cy3 (Jackson Immuno-Research, West Grove, PA). Vectashield mounting medium with 4',6'-diamidino-2-phenylindol (DAPI) was then applied (Vector Laboratories, Burlington CA). Images were collected using a BioRad Radiance 2000 Laser Scanning Confocal Microscope.

25        Repression assays. Reporter assays were performed in 293 T cells seeded at a density of  $5 \times 10^5$  cells per well of a twelve well dish. 100 ng of either (GAL4)-TK-Luc and (BCL6)-TK-Luc reporters were co-transfected with 10 ng of TK-Renilla internal control plasmid using Superfect (Qiagen). Lysates were submitted to dual luciferase assays as per the manufacturer’s protocol 30 (Promega). Equivalent levels of protein expression from the transfected

plasmids was verified by immunoblotting with rabbit polyclonal GAL4<sup>1-147</sup> (sc-577) antibodies or mouse monoclonal BCL6 (D8) antibodies (Santa Cruz).

Accession Numbers. The coordinates for the form I, form II and BBD peptide complex crystal structures of the BCL6 BTB domain have been deposited 5 to the Protein Data Bank with accession codes 1R29, 1R28 and 1R2B, respectively.

**Example 2. Dissecting the BCL6 Repressosome *in vivo* as Transcription Therapy for B-cell Lymphomas.**

Example Summary

10 The BTB/POZ transcriptional repressor Bcl-6 is frequently misregulated in B-cell lymphomas. We identified the interface through which the BCL6 BTB domain mediates recruitment of the SMRT, N-CoR and BCoR corepressors. To determine the contribution of this interaction to BCL6 mediated gene silencing and lymphomagenesis we generated specific peptide inhibitors that penetrate 15 cells, bind BCL6 and block corepressor recruitment. These peptides modified the chromatin structure of BCL6 target promoters, abrogated BCL6 mediated repression, reactivated BCL6 target genes, and induced apoptosis and cell cycle arrest in B-cell lymphoma cells. Therefore, SMRT, N-CoR and BCoR play essential roles in BCL6 repression and are required for BCL6 to maintain the 20 malignant phenotype of diffuse large B-cell lymphoma cells. BCL6 BTB blockade may thus constitute a novel form of targeted transcription therapy.

Research Rationale, Results and Discussion

The BTB/POZ domain is a highly conserved ~120 residue polypeptide motif found in over 200 human proteins. A subfamily of BTB proteins contain 25 C-terminal DNA binding motifs (usually C2H2 zinc fingers) and function as transcriptional repressors, several of which are implicated in human cancers including the BCL6, PLZF and Hic-1 proteins. In all of these proteins, the BTB domain is required for transcriptional repression, dimerization, oligomerization,

and localization to specific nuclear compartments. We are interested in the mechanisms of action of these transcriptional repressors and the role of the BTB domain in the molecular pathophysiology of human cancer. We previously showed that BTB domains mediate obligate homo-dimerization through a 5 conserved hydrophobic face and oligomerization through a separate hydrophobic surface region. These architectural features are conserved and swappable among BTB proteins and required for their biological functions.

BTB domains also mediate repression through actions specific to each protein. In particular, the BCL6 BTB domain is a potent repressor that directly 10 binds SMRT, N-CoR and BCoR corepressors in a mutually exclusive manner. Mapping experiments indicated that these corepressors bind the BCL6 BTB domain through a conserved 17 residue motif (hereon called "CoR motif"). Crystallographic analysis of the BCL6-BTB/CoR motif complex revealed that the CoR motif directly binds a "lateral groove" motif specific to the BCL6 BTB 15 domain (FIG. 7A). The lateral groove-CoR motif interaction plays a key role in BCL6 interaction with SMRT, N-CoR and BCoR in vivo and is required for BTB domain-mediated transcriptional repression of reporter constructs.

Transcriptional repression of target genes is the only known action of BCL6, and is attributed in large part to the BTB domain. However, the BCL6 20 ZnFs participate in repression as well by recruiting the ETO corepressor and class II HDACs and a medial region of BCL6 also has repressor activity. In addition to repression through direct binding to target genes, BCL6 may function as a corepressor for AP-1 in a BTB domain-dependent manner and to reduce GATA-3 protein levels through a post-transcriptional mechanism. The 25 relevance and hierarchy of each of these domains and mechanisms of BCL6 gene regulation are unknown. Finally, little is known of what contributions are made to endogenous transcriptional repression by SMRT/N-CoR and BCoR and how this impacts on the biological actions of their partner transcription factors.

Regulatory elements of the BCL6 gene are frequently mutated in human 30 diffuse large B-cell lymphomas (DLBCL) by chromosomal translocations or

somatic hypermutation. This leads to inappropriately timed expression of BCL6, which is otherwise tightly controlled in B-cells. Normally, BCL6 detains antigen-stimulated B-cells in lymphoid follicles to form germinal centers and permits maturation of activated B-cells to high-affinity immunospecific

5 lymphocytes. In lymphomas, sustained BCL6 expression is postulated to favor B-cell proliferation and survival in the face of ongoing mutagenesis by the somatic hypermutation machinery. In spite of intensive studies, and its consideration as a molecular marker of disease prognosis in B-cell lymphomas, it is not known whether BCL6 is required to maintain the malignant phenotype

10 of tumor cells and whether such a role is restricted to cells with mutations in the BCL6 gene (40% of cases), or to all BCL6 positive B-cell lymphomas (80% of cases).

Since our previous data (Example 1) indicate that the lateral groove-CoR motif interaction is a critical interface for SMRT/N-CoR/BCoR recruitment to

15 the BCL6 BTB domain, we reasoned that lateral groove blockade offers the unique possibility of determining the contribution of these corepressors to transcriptional and biological actions of BCL6, the contribution of BCL6 repression to its biological actions and, the contribution of BCL6 to the malignant phenotype of different classes of B-cell lymphomas. Finally, were

20 BCL6 to require lateral groove corepressor recruitment for oncogenic effects, blocking reagents would constitute a highly specific and potent form of transcription therapy for human patients with these diseases.

To test this hypothesis, a peptide inhibitor (WP) was designed (FIG. 7B), consisting of four basic elements: an N-terminal (His)6 tag for affinity

25 purification, a protein transduction domain (PTD) from the HIV pTAT protein for peptide delivery into the cells (Frankel and Pabo, 1988), a hemagglutinin (HA) epitope tag for immunodetection, and the human SMRT CoR motif (residues 1414-1430), for specific binding to the BCL6 lateral groove (FIG. 7B). As a negative control a mutant peptide (MP) was engineered where the CoR

30 motif contained an EIPR->AAAA mutation, which we previously showed

(Example 1) abrogates binding to BCL6. These peptides were expressed in *E. coli* and purified from the insoluble fraction of bacterial lysates.

To verify transduction and intracellular localization, B-cell lymphoma cells (Ly1, Ly4 and Ly8 DLBCL cells, Raji and Daudi Burkitt lymphoma cells) 5 and 293T cells were treated with several different concentrations of purified WP and MP. Whole cell lysates, cytoplasmic and nuclear extracts were obtained and western blots performed with  $\alpha$ -HA antibodies to detect the peptides (FIG. 7C). Both WP and MP peptides efficiently penetrated cells and localize preferentially in the nucleus. We previously showed that the CoR motif binds to Bcl-6 but not 10 other BTB proteins. To confirm specific binding of our peptides to Bcl-6, Ly1 nuclear extracts were mixed with peptide buffer (CB), or 1  $\mu$ M of WP or MP respectively. Ly1 cells are used extensively in these studies, since they are derived from a DLBCL patient with BCL6 gene exon 1 mutations that cause loss 15 of Bcl-6 autoregulation - and are thus a potentially "Bcl-6 dependent" tumor.

15 Co-immunoprecipitations (Co-IP) using anti-BCL6 antibodies were performed followed by western blot against the HA epitope of the peptides (FIG. 7D). Consistent with our expectations, WP but not MP interacted with 20 endogenous Bcl-6 from Ly1 cells. Similar results were obtained using Lysates from 293T cells transfected with full-length BCL6 and exposed to BP or 1  $\mu$ M WP or MP for one hour (FIG. 7E).

We next determined whether lateral groove binding by WP peptide could 25 displace the SMRT corepressor in vivo. Co-immunoprecipitations between SMRT or N-CoR with Bcl-6 are challenging with existing antibodies and hence there are no examples of such experiments in the literature. Accordingly, we found that coimmunoprecipitation of Bcl-6 with endogenous corepressors cells was elusive since these proteins are expressed at low levels. However, by 30 extensive optimization we obtained reproducible co-immunoprecipitations between Bcl-6 and SMRT in transfected 293T cells. Forty-eight hours after transfection, the cells were exposed to either PB, or 1  $\mu$ M WP or MP for one hour. Remarkably, the WP peptide consistently abrogated SMRT binding to

Bcl-6, whereas the mutant peptide failed to do so (FIG. 7F). Bcl-6 normally localizes in nuclear speckles, where it colocalizes with SMRT. By transfecting low levels of Bcl-6 and SMRT in 293T cells we were able to reproduce the endogenous staining pattern of BCL6 and SMRT. The impact of lateral groove 5 blockade on BCL6-SMRT colocalization was determined by exposing these cells to PB, WP or MP as described above. Cells were then co-stained for Bcl-6 and SMRT or Bcl-6 and HA and visualized in sections by confocal microscopy (FIG. 7G). We found that Bcl-6 and SMRT colocalization occurred in the presence of PB or 1  $\mu$ M MP, but was disrupted in presence of 1  $\mu$ M WP. Reciprocally, Bcl-6 10 colocalized with WP but not MP, indicating that WP peptide binding was mutually exclusive with corepressor binding, and that the BTB lateral groove contact site is necessary and sufficient for SMRT binding to Bcl-6 in vivo. Furthermore, structure guided design of blocking molecules can lead to 15 production of effective inhibitors of transcription factor-corepressor interactions proteins.

Our previous data indicate that lateral groove point mutations disrupt transcriptional repression by the BCL6 BTB domain, consistent with loss of corepressor recruitment. We reasoned that since WP peptides block SMRT binding to BCL6, BTB domain-mediated transcription would be impaired. To 20 determine whether this is the case, 293T cells were transfected with a GAL4-Bcl-6<sup>BTB</sup> fusion expression vector and a GAL4 responsive reporter construct and an internal control reporter. Twenty four hours after transfection, cells were exposed to PB, WP, MP or nothing over the next 20 hours. Remarkably, WP but not MP or PB abrogated BCL6 BTB domain transcriptional 25 repression (FIG. 8A). Growth and viability of 293T cells was unaffected by any of these reagents and the protein levels of GAL4Bcl-6<sup>BTB</sup> fusions was equivalent in all samples (data not shown).

Other BTB domains autonomously repress transcription, yet none appear to contain lateral groove motifs. For example, the PLZF BTB domain also 30 directly interacts with and requires SMRT and N-CoR, though interaction seems

to occur through a distinct charged pocket motif, while the HIC-1 BTB domain also mediates repression but does not interact with SMRT or N-CoR. Therefore, transcriptional repression by these BTB domains should not be affected by the WP peptide. Accordingly, in contrast to BCL6, transcriptional repression by the  
5  $\text{GAL4-PLZF}^{\text{BTB}}$  or  $\text{GAL4-HIC1}^{\text{BTB}}$  proteins were unaffected by WP or negative controls (FIG. 8A). These results suggest that the lateral groove - CoR motif mechanism is specific to Bcl-6 and not other BTB proteins, consistent with our bio-informatic predictions.

We next wished to determine the hierarchy of the lateral groove  
10 mechanism, i.e. the contribution of the CoR motif corepressors, to transcriptional repression by full-length BCL6. Full length BCL6 was expressed together with a  $(\text{BCL6})_3$  binding site-TK-Luc reporter and then exposed to increasing doses of WP or MP peptides (250 nM, 500 nM and 1  $\mu\text{M}$ ) followed by peptide treatment as above. WP but not MP caused a dose-dependent  
15 reduction of Bcl-6 transcriptional repression, but did not completely abrogate it (FIG. 8B), suggesting that the remaining BCL6 domains mediate residual repression independent of SMRT/N-CoR/BCoR. Alternatively, loss of Bcl-6 repression may be underestimated by the lag time between transfection and peptide exposure. Finally, the SMRT/N-CoR/BCoR corepressors normally  
20 enhance transcriptional repression by BCL6 in reporter assays. Not surprisingly, lateral groove blockade with WP inhibits enhancement of Bcl-6 repression by BCoR and SMRT (FIG. 8C).

Transcriptional regulation differs in episomal reporter genes vs. the structured chromatin context of endogenous gene loci. The most significant  
25 measure of lateral groove effect is thus whether peptide blockade of endogenous BCL6 re-activates endogenous direct BCL6 target genes. We exposed three DLBCL cell lines: Ly1 (mutated BCL6 exon1), Ly8 (BCL6 translocation), Ly4 (Non mutated BCL6 locus) to buffer, or 1  $\mu\text{M}$  WP or MP for 6 hours, extracted mRNA and performed real time PCR on BCL6 target genes. WP peptide  
30 re-activated BCL6 target genes such as CD80 5-8 fold and cyclinD2 2-4 fold in

Ly1 and Ly8 cells, whereas there was no effect in Ly4 cells (FIG. 8D). In contrast, MP had little effect on BCL6 target gene expression. Although BCL6 autoregulates its own expression, there was no detectable re-activation in these lymphoma cells, most likely since Ly1 and Ly8 have lost the BCL6 regulatory elements in the mutated alleles. These studies offer direct evidence that the CoR motif proteins function as corepressors *in vivo*, and their interaction with the BTB domain is required to maintain silencing by the endogenous Bcl-6 protein.

To determine whether the effects of WP peptide on repression might be caused by interfering with BCL6 binding to DNA, we next performed electrophoretic mobility assays. Nuclear extracts of transfected 293T cells were allowed to bind radiolabeled oligonucleotides containing either one or three Bcl-6 binding sites. Different concentrations of WP or MP were added to the reaction and unlabeled DNA probe, anti-Bcl-6 antibodies or control IgG were used to verify the specificity of the observed complexes. Interestingly, addition of WP caused a dose dependent reduction in the main BCL6-DNA complex in favor of a faster migrating specific complex, with no apparent reduction in overall DNA binding. Furthermore, DNA binding by the BCL6 zinc finger only constructs was unaffected by WP or MP peptides, nor was there any change in the size of the DNA-protein complex (not shown). Results with the single or triple binding site probe were identical, and only the former is shown in FIG. 9A. The same result was seen in nuclear extracts with endogenous BCL6 from Ly1 cells (data not shown).

Disruption of the high molecular weight complex by lateral groove blockade is likely due to loss of CoR motif corepressors from the BCL6 complex. However, attempts to supershift SMRT and N-CoR from these high molecular weight complexes were unsuccessful (consistent with the experience of other investigators) with the available antibodies. Furthermore, from the physiological standpoint the relevant BCL6 complexes in transcriptional repression are those that form on the promoters of endogenous Bcl-6 target

genes. Endogenous complexes were analyzed by chromatin immunoprecipitations (ChIPs) in the BCL6 positive Ly1 and Ly8 cells after one-hour exposure to WP, MP or buffer. The cross-linked chromatin was pulled down with antibodies against BCL6, SMRT, N-CoR and HA (for the peptide).

5 PCR was performed on the purified DNA using specific primers for BCL6 binding sites of the MIP1 $\alpha$  promoter, which we have used previously to map BCL6 recruited proteins by ChIPs (FIG. 9B). BCL6 itself bound the MIP1 $\alpha$  promoter in the presence of both WP and MP peptides, confirming that lateral groove blockade does not interfere with binding to target genes. In contrast, SMRT and

10 N-CoR were both excluded from the MIP1 $\alpha$  promoter in the presence of WP but not MP peptide. Finally, the WP but not MP peptide was associated with the MIP1 $\alpha$  promoter by ChIPs consistent with its binding to the BTB domain and displacing corepressors. These results indicate that endogenous BCL6 repressosome formation includes the SMRT and N-CoR proteins and that this

15 complex is disrupted by lateral groove blockade.

Transcriptional repressors recruit corepressors to mediate changes in chromatin structure that lead to silencing of the targeted locus. Two such modifications associated with silencing include deacetylation of histone tails and the methylation of lysine 9 of the tail of histone 3. Accordingly, the SMRT 20 corepressor is directly implicate in histone deacetylation. ChIP assays performed in Ly1 and Ly8 cells on the MIP1 $\alpha$  promoter indicate that histone 4 tails are deacetylated at baseline but become acetylated in the presence of WP peptide, indicating that CoR motif corepressors mediate deacetylation of histones by BCL6. We also found that BCL6 target genes were methylated on 25 lysine 9 of histone 3. Although a connection between SMRT/N-CoR and histone methylation has not yet been reported, we found that these corepressors were also required for H3-K9 methylation by BCL6. These results suggest that these very large CoR motif corepressors repress transcription of BCL6 target genes by acting as a scaffold for histone deacetylases and histone methyltransferases.

Loss of this scaffold through lateral groove blockade leads to erasure of these chromatin modifications with consequent target gene reactivation.

BCL6 is the most commonly mutated gene in B-cell lymphoma, based on which it is widely implicated as a potential oncogene. This view is supported by 5 the identity of certain BCL6 target genes involved in cell cycle control, apoptosis and differentiation. We reasoned that if BCL6 repression is oncogenic, re-activation of target genes by lateral groove blockade might profoundly alter the phenotype of lymphoma cells. Tumors most likely to respond to WP peptides are those derived from patients with activating mutations in the BCL6 10 gene, which are presumably BCL6-dependent and include 40% of DLBCL cases, 16% of follicular lymphoma cases, and a significant percentage of AIDS-related lymphomas. In contrast, B-cell lymphomas that express BCL6 but do not have mutations, or that do not express BCL6 might not be BCL6 dependent.

To determine if this is case, the biological effects of lateral groove 15 inhibition were tested in the following DLBCL cells: Ly1 and Ly8 (BCL6 mutated), Ly4 (BCL6 negative), Ly7 (BCL6 positive-not mutated), Ly10 (activated B cell type DLBCL); Germinal center Burkitt Lymphoma Daudi and Raji Cells (BCL6 positive - not mutated), Ly12 cells (T-cell lymphoma - low BCL6 expression) and U937 monocytic leukemia cells. Lymphoma cells were 20 treated for 48 hours with peptide buffer or 1  $\mu$ M WP or MP peptides and the effects of these treatments on survival, cell cycle and differentiation analyzed.

Apoptosis was measured by sub G1/G0 population scoring and Annexin V staining. Remarkably, within 48 hours, 40-50% of the Ly1 cells underwent programmed cell death with WP but not MP or PB. Furthermore, flow 25 cytometry of propidium iodide stained Ly 1 cells of WP indicated that a minority of cells were still viable (FIG. 10A). In contrast, the predicted non-BCL6 dependent cell lines were not affected by peptide treatment, with the exception of Raji cells (20% apoptosis with WP). This result is consistent with Shaffer et al (2000) where a BCL6 zinc fingers- estrogen receptor activation domain fusion 30 protein caused mild apoptosis, and may indicate that BCL6 may participate in

maintaining the malignant phenotype in a subset of tumors where the gene is wild type. Similar results were obtained in XTT metabolic viability assays (10B). Cell cycle analysis was performed by propidium iodide staining followed by flow cytometry (FIG. 10C). WP but not mutant peptide induced G1 arrest in 5 Ly1, Ly8 and Raji cells but not in the other cells. These results show that BCL6 is necessary to maintain the malignant phenotype of this kind of B-cell lymphomas. BCL6 is hypothesized to block differentiation of B-cells by repressing the Blimp-1 master regulator of plasma cell differentiation. Our flow cytometry analysis of differentiation markers CD10, CD38 and CD138 indicate 10 that lateral groove blockade does not induce differentiation in any of the B-cell lines analyzed (FIG. 10D). This indicates that either Bcl-6 is not involved in blocking differentiation, or that putative BCL6 target genes involved in differentiation are not regulated by CoR motif corepressor recruitment. Taken together, these results suggest that BCL6 expression is required for survival and 15 proliferation of B-cell lymphomas containing BCL6 activating mutations, and may play a role in a subset of non-mutated B-cell lymphomas.

Transcriptional repression occurs through the coordinated actions of protein complexes recruited to specific target genes by sequence specific transcription factors. The composition of these repressosomes may vary from 20 locus to locus, suggesting that different cofactors are involved in regulating different sets of target genes. The specific set of protein-protein interactions that occur in these repressosomes determine the transcriptional outcome as detected by changes in chromatin structure and mRNA expression. We designed a peptide reagent, able to specifically and "cleanly" subtract the 25 contribution of the SMRT/N-CoR/BCoR corepressors from the transcriptional actions of the BCL6 protein. Our results offer direct evidence of the role of these corepressors in endogenous target gene chromatin modification, endogenous transcriptional regulation, and in transcription factor specific biological effects. The fact that lateral groove blockade uncovered the 30 requirement of BCL6 transcriptional repression for survival of DLBCL cells with

BCL6 mutations suggest that Bcl-6 is truly a lymphoma oncogene and not just a marker of cells that have traversed germinal center differentiation.

Finally, in experimental cancer therapy, much attention has been focused on therapeutic re-expression of silenced genes (transcription therapy) with a particular emphasis on the development of drugs that inhibit enzymatic activities, such as histone deacetylase inhibitors. However, the most successful transcription therapy drug is also the only one that directly targets the interaction of a transcriptional repressor with its partner corepressors - i.e. all trans retinoic acid targeting of the PML/RAR $\alpha$  oncoprotein in acute promyelocytic leukemia. Similarly, our results suggest that our lateral groove blocking peptide drug is a novel and promising structure guided specific transcription therapy agent. Therefore, we have initiated pre-clinical studies with chemical derivatives with the intent to move into clinical trials in patients with DLBCL.

15 **Materials and Methods**

Expression and purification of peptides. The (His)6-pTAT-HA bacterial expression plasmid were obtained from Dr. Steve Dowdy (UCSD).

Oligonucleotides containing the wild type

(5'-CATGGCTGGTGGCCACGGTGAAGGAGGCGGGCCGCTCCATCCATGAGATCC  
20 CGCGCGAGGAGCTCGGCACACGCCGAGCTGCCCTGGCCC-3' and 5'-  
TCGAGGGCCAGGGGCAGCTCGGGCGTGTGCCAGCTCCTCGCGCGGGATCTCA  
TGGATGGAGCGGCCGCCTCCTCACCGTGGCCACCAGC-3') or mutant CoR  
motif (5'-CATGGCTGGTGGCCACGGTGAAGGAGGCGGGCCGCTCCATCC  
ATGCAGCTGCAGCTGAGGAGCTCGGCACACGCCGAGCTGCCCTGGCCC-3'  
25 and 5'- TCGAGGGCCAGGGCAGCTCGGGCGTGTGCCAGCTCCTCAG  
CTGCAGCTGCATGGATGGAGCGGCCGCCTCACCGTGGCCACCAGC-3')  
CoR motif sequences were inserted into *Nco*I and *Xho*I sites, and the construct verified by automated sequence (Albert Einstein Sequencing Facility). Peptide expression was induced with IPTG in *BL21(D3)* *E. coli* cells (Novagen), which  
30 were harvested by centrifugation, washed with PBS and resuspended in lysis

buffer (50 mM Tris-HCl pH8, 150mM NaCl, 5% Glycerol). Lysozyme (1 mg/ml) was added and incubated for 30 min at 4 °C followed by sonication using a Vibra Cell sonicator (Sonic & Material Inc). The sample was centrifuged at 12000 rpm in a Sorvall RC5B centrifuge, and resuspended in a peptide buffer

5 (PB=20 mM Phosphate pH=7.4 10 mM imidazole, 150 mM NaCl, 5% Glycerol, 4 M urea) and affinity purified by Ni-NTA Hi-Trap column (Pharmacia Biotech) using an AKTA Purifier 10 (AP Biotech). The purity of peptide fractions was verified by 15% tricine SDS-PAGE followed by Coomassie Blue staining (Bio-Rad) or by Western Blot using HA polyclonal antibodies (Sigma).

10 Peptide transduction. Cells were exposed to different concentrations (100 nM, 250 nM, 500 nM, 1 µM) of WP and MP peptides for 2 hours and harvested at different time points. The cells were then washed 4 times with PBS, and whole cell lysates obtained using a Lysis Buffer= 50 mM Hepes, 0.1% NP-40, 50 mM NaCl, or the pellet was fractionated by resuspending the pellet in 15 a buffer of 10 mM Hepes-KOH pH= 7.9, 10 mM KCl, 0.5 mM DTT, 0.5 mM PMSF, 10 µM Leupeptin on ice for 10 minutes. After treatment in a microcentrifuge at maximum speed (15 min.), the supernatant was saved as the cytoplasm fraction. The pellet was then resuspended in a buffer of 10 mM Hepes-KOH pH= 7.9, 25% glycerol, 410 mM NaCl, 1.5 mM MgCl<sub>2</sub>, 0.2 mM

20 EDTA, 0.55 mM DTT, 0.5 mM PMSF on ice. After 20 minutes the sample was again centrifuged at maximum speed for 15 minutes. The supernatant was saved as the nuclear extract. The peptides were visualized by loading the fractions as well the whole cell lysates in 15% tricine SDS-PAGE followed by Western Blot using HA polyclonal antibodies (Sigma).

25 Coimmunoprecipitations. For in vitro coimmunoprecipitations, Ly1 and 293 T cell nuclear extracts were obtained as described above and incubated with the PB, or WP and MP peptides at a final concentration of 0.12 mg/ml. For in vivo coimmunoprecipitations, 293 T cells were transfected with 4 µg of BCL6 expression vector (REF) using Superfect (Qiagen). Forty-eight hours later 30 the cells were exposed to PB, or the WP or MP peptides for 1 hour, washed 4

times with PBS, and lysed in a buffer of 50 mM Hepes, 0.1% NP-40, 50 mM NaCl. *In vitro* and *in vivo* samples were precleared with a mix of Protein G/A agarose beads (Roche, Mannheim, Germany), incubated overnight with BCL6 D-8 monoclonal antibodies (Santa Cruz) and pulled down with G/A agarose beads (Roche) for 2 hours. The pellet was washed 3 times with lysis buffer, resuspended in 2x loading buffer and analyzed by Western blot with HA polyclonal antibodies (Sigma).

Immunofluorescence.  $1 \times 10^6$  293T Cells were plated in 22 mm sterile glass coverslips and placed in 6 well dishes. 24 hours later cells were 10 transfected with 100 ng pEF-BCL-6 and/or 200 ng CMX-SMRT or pEF vector using the Superfect reagent (Qiagen). pBluescript was added to 3000 ng per well. Immunostaining was performed as previously reported (REF). Bcl-6, SMRT and peptides were detected using BCL-6 monoclonal antibodies (Dako, Fort Collins, Co), SMRT polyclonal antibodies (Upstate Biotechnologies, 15 Waltham, MA) or HA polyclonal antibodies (Sigma), followed by donkey anti-mouse and/or anti-rabbit secondary antibodies (Jackson Immuno Research, West Grove, PA) conjugated to Cy2 and Cy3 respectively. Confocal microscopy was performed using a Leica AOBS Laser Scanning Confocal Microscope (Leica) in the Albert Einstein Analytical Imaging Facility. Images were captured in each 20 channel independently in non-overlapping spectra. Each experiment was repeated at least 3 times in duplicates and multiple fields imaged and captured.

Reporter assays. 293T cells were plated in a 12 well dish at a density of  $2 \times 10^5$  per well or in a 24-well dish at  $1 \times 10^5$  per well (Invitrogen, Carlsbad, CA), and transfected with 100 ng of either  $(GAL4)_5\text{-TK-Luc}$  or  $(BCL6)_4\text{-TK-Luc}$  and 25 cotransfected with the corresponding expression vectors indicated in the figure legends, plus a renilla reporter construct as an internal control, using Superfect (Qiagen, Valencia, CA). After 24 hrs cells were treated with PB, MP or WP at a final concentration 1  $\mu\text{M}$  for 20 hrs, adding fresh peptide every 2.5 hrs. Cells were harvested and dual luciferase assays were performed (Promega, Madison, 30 Wisconsin) according to the manufacturer's instructions. Luciferase activity was

read in a POLARstar Optima microplate luminometer (BMG Labtechnologies, Durham NC). All transfections were performed in quadruplicate and repeated at least 3 times. Lysates were subjected to western blot to verify protein expression from transfected vectors.

5        Real-time PCR. 10<sup>7</sup> Ly1, Ly8 or Ly4 cells were harvested after no treatment or treatment with PB or 1 µM of WP or MP for 7.5 hours, adding fresh peptide every 2.5 hours. RNA was extracted from the cells using TRIzol ® Reagent (Invitrogen). cDNA was synthesized from 10 µg of RNA using the Superscript II™ First Strand cDNA Synthesis System kit (Invitrogen). 1 µl of 10 cDNA for each condition in a final volume of 20 µl was used in real-time PCR analysis using the QuantiTect SYBR® Green PCR kit (QIAGEN) in a DNA Engine Opticon 2® System thermal cycler (MJ Research). mRNA levels of Bcl-6 target genes were normalized to endogenous levels of HPRT mRNA and calculated relative to buffer using the ΔΔC<sub>t</sub> method. The peptide treatment of the cells 15 was performed two or three times and real-time PCR experiments were repeated four times with each reaction/conducted in triplicate.

The following primers were used:

CD80-F: CATCCTGGGCCATTACCTTA,

CD80-R: TCTCTCTCTGCATCTGGGG,

20 BCL6-F: GACTCTGAAGAGGCCACCTGC,

BCL6-R:CTGGCTTTGTGACGGAAAT,

CYCLIND2-F: CCGGACCTAATCCCTCACTC,

CYCLIND2-R: CACACCGATGCAGCTTCTA,

HPRT-F: AAAGGAACCCCACGAAGTGTT

25 HPRT-R: TCAAGGGCATATCCTACAACAA

Chromatin immunoprecipitation. 10x10<sup>7</sup> Ly1 and Ly8 cells were treated with PB or 1 µM WP or MP peptides for 7.5 hours adding fresh peptide every 2.5 hours. Cells were fixed in 1% formaldehyde (Fisher) (50 mM Hepes pH 8.0, 1mM EDTA, 100 mM NaCl, 0.5 mM EGTA, 37% formaldehyde) for 10 min at

room temperature and quenched by 0.125 M glycine for 10 min. Cells were washed twice with ice-cold PBS and resuspended in 4 ml of lysis buffer (1% SDS, 10 mM EDTA pH 8.0, 50 mM Tris-HCl pH 8.0) at 4 °C for 10 minutes. The lysates were sonicated 5 x 30 seconds at an amplitude of 55% in a Ultrasonic

- 5 5 Dismembrator Model 500 (Fisher) to obtain chromatin fragments with an average size of 300-500 bp, centrifuged at 14,000 rpm for 10 minutes and the supernatants precleared with a mixture of protein A/G agarose beads (Roche). 10% input was collected at this point for later analysis. Specific immunoprecipitations (each on ~10 x10<sup>6</sup> cells) were performed using rabbit 10 polyclonal antibodies for Bcl-6 (N-3),  $\alpha$ N-CoR (H-303) (Santa Cruz), SMRTe, histone 4 pan-acetylated and histone 3 Lysine 9 dimethyl (Upstate Biotechnologies), HA (Sigma), normal rabbit serum (Jackson Immuno Research) or water control overnight at 4 °C. DNA-protein complexes were pulled-down by mixing with protein A/G agarose beads at 4 °C for 30 minutes 15 and washed twice with each of the following buffers for 10 minutes at RT: 1.- 0.1% SDS, 1% Triton X-100, 2 mM EDTA pH 8.0, 20 mM tris-HCl pH 8.0, 150 mM NaCl; 2.- 0.1% SDS, 1% Triton X-100, 2 mM EDTA pH 8.0, 20 mM Tris-HCl pH 8.0, 500 mM NaCl; 3.- 0.25M LiCl, 1% NP-40, 1% Na-Deoxycholate, 1 mM EDTA pH 8.0 and 10 mM tris-HCl pH 8.0; and finally TE (10 mM Tris, 1mM 20 EDTA pH 8.0). After the last wash, the beads were resuspended in 100  $\mu$ l of Elution Buffer (1% SDS, 0.1M NaHCO<sub>3</sub>), incubated overnight at 65 °C overnight to reverse cross-links and purified using QIAquick PCR purification columns (Qiagen). The resulting DNA fragments were detected by 45 cycles of PCR in a GeneAmp 9700 thermal cycler (Perkin-Elmer-ABI). The following primers were 25 used: MIP-1 $\alpha$  promoter: S-5'-ACGATGCTGGGTCAGGTATC-3'  
AS-5'-AGTGACTAGGGCGCTGTGTT-3' (192 bp product) and Bcl-6 exon1:  
S-5'-GGGTTCTTAGAAGTGGTGATGC-3' AS-5'-TGGGACTAATCTCGGCATT-3',  
and a Bcl-6 intron 7 negative control S-5'-CGATGAGGAGTTCGGGATGT-3'  
AS-5'-TTTCTGGGGCTCTGTGGACT-3'. These experiments were performed

four times and the immunoprecipitations with each antibodies were performed in duplicates in each of the four experiments.

Cell viability. Ly1, Raji and U937 cells were treated with BP, MP, or WP during 48 hours, during that period of time fresh peptide or BP was added every 5 3 hours, changing the media every 6 hours. Cell viability was determined using the Tox2 XTT bases kit (Sigma) following manufactured instruction. Briefly, XTT solution was added in a final concentration of 20% v/v of the cultured media cells plated in 96 wells plate. The cells were incubated for 4 hours and the  $A_{450}$  determined using a MRC Revelation microplate reader (Dinex 10 Technologies, West Sussex, UK). The experiment was performed twice in quadruplicate.

FACS analysis. The cells lines were treated with BP, MP, or WP for 48 hours, with fresh peptide or BP added every 3 hours, and the media changed every 6 hours. After treatment, the cells were harvested, washed with PBS 3% 15 BSA (Sigma), resuspended at  $1 \times 10^6$  cells/50  $\mu$ L in PBS/3% BSA/0.1%  $\text{NaN}_3$ . The cells were immunostained with 5  $\mu$ l CD10-R-PE and CD38-APC antibodies (Caltag, Burlingame, CA) per  $10^6$  cells and incubated on ice for 30 min. The cells were then washed twice with PBS/3% BSA/0.1%  $\text{NaN}_3$  and resuspended in 500  $\mu$ L PBS/3% BSA/0.1%  $\text{NaN}_3$ . The samples were analyzed on a FACSCalibur 20 or FACScan flow cytometer (Beckton Dickinson) using the CellQuest program (BD Bioscience, San Jose, CA).

For cell cycle analysis and apoptosis quantification the cells were fixed in cold 70% ethanol and stored until staining. Before staining, the cells were washed twice in PBS and resuspended in 1 ml of PBS. The cells were then 25 stained with 50  $\mu$ L of propidium iodide (Sigma)(1mg/ml) and 20  $\mu$ l of ribonuclease A(Sigma)(10  $\mu$ g/ml). The cells were incubated for 2 hours at 4 °C and then measured by flow cytometry in a FACScan. Cells in pre G1/G0 (hypodiploid DNA) were considered apoptotic. The CellQuest program was used for quantification; cell cycle was analyzed using ModFit software (Verity

Software House, Inc, Topsham, ME). All experiments were performed between 3 and 6 times.

In view of the above, it will be seen that the several advantages of the invention are achieved and other advantages attained.

- 5        As various changes could be made in the above methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.
- 10       All references cited in this specification are hereby incorporated by reference. The discussion of the references herein is intended merely to summarize the assertions made by the authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinence of the cited references.

Appendix - SEQ ID NO:s

SEQ ID NO:1 - SMRT corepressor BCL6 binding peptide - 17mer

lvatvkeagrsiheipr

SEQ ID NO:2 - N-CoR corepressor BCL6 binding peptide - 17mer

5   gittikemgrsiheipr

SEQ ID NO:3 - BCoR corepressor BCL6 binding peptide - 17mer

sragsglvlsgseipke

SEQ ID NO:4 - SMRT corepressor BCL6 binding peptide - 21mer

glvatvkeagrsiheipreel

10   SEQ ID NO:5 - N-CoR corepressor BCL6 binding peptide - 21mer

dgittikemgrsiheiprqdi

SEQ ID NO:6 - BCoR corepressor BCL6 binding peptide - 21mer

hsragsglvlsgseipketle

SEQ ID NO:7 - SMRT corepressor BCL6 binding peptide - 29mer

15   glvatvkeagrsiheipreelrhtpelp

SEQ ID NO:8 - N-CoR corepressor BCL6 binding peptide - 29mer

dgittikemgrsiheiprqdiltqesrkt

SEQ ID NO:9 - BCoR corepressor BCL6 binding peptide - 29mer

hsragsglvlgseipketleppgngcai

What is claimed is:

1. A compound that binds to a BCL6 lateral groove and prevents binding of a corepressor to the lateral groove.
2. The compound of claim 1, wherein the compound is an organic molecule less than 1000 molecular weight.
3. The compound of claim 1, wherein the compound is an aptamer.
4. The compound of claim 1, wherein the compound is a peptide or mimetic comprising the sequence eipx, where x is a basic amino acid or analog.
5. The peptide or mimetic of claim 1, comprising SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or a sequence combining aligned residues thereof.
6. The peptide or mimetic of claim 5, comprising SEQ ID NO:1.
7. The peptide or mimetic of claim 5, comprising SEQ ID NO:2.
8. The peptide or mimetic of claim 5, comprising SEQ ID NO:3.
9. The peptide or mimetic of claim 5, having 84 or less amino acid or analog residues.
10. The peptide or mimetic of claim 5, having 21 or less amino acid or analog residues.

11. The peptide or mimetic of claim 5, having 17 amino acid or analog residues.
12. The peptide or mimetic of claim 1, further comprising at least one functional group.
- 5 13. The peptide or mimetic of claim 12, wherein the functional group is a moiety that facilitates purification.
14. The peptide or mimetic of claim 13, wherein the moiety that facilitates purification is a (His)<sub>6</sub> moiety.
- 10 15. The peptide or mimetic of claim 12, wherein the functional group is a moiety that facilitates entry of the peptide or mimetic into a cell.
16. The peptide or mimetic of claim 15, wherein the moiety that facilitates entry of the peptide or mimetic into a cell is a protein transduction domain from the HIV pTAT protein.
17. The peptide or mimetic of claim 12, wherein the functional group is a moiety that facilitates detection of the peptide or mimetic.
18. The peptide or mimetic of claim 17, wherein the moiety that facilitates detection of the peptide or mimetic is a fluorescent moiety, a radioactive moiety, or an antigen.
19. The peptide or mimetic of claim 4, wherein the moiety that facilitates detection of the peptide or mimetic is a hemagglutinin epitope tag.

20. The peptide or mimetic of claim 4, wherein the peptide or mimetic further comprises a (His)<sub>6</sub> moiety, a protein transduction domain from the HIV pTAT protein, and a hemagglutinin epitope tag.

21. The compound of claim 1, in a pharmaceutically acceptable  
5 excipient.

22. A method of blocking corepressor binding to a BCL6 lateral groove, the method comprising contacting the BCL6 with the compound of claim 1.

23. The method of claim 12, wherein the BCL6 is in a mammalian cell.

24. The method of claim 23, wherein the mammalian cell is a cancer cell  
10 that requires BCL6 repression.

25. The method of claim 23, wherein the cancer cell is in a mammal.

26. The method of claim 25, wherein the mammal is a human.

27. The method of claim 24, wherein the cancer cell is a lymphoma cell.

28. The method of claim 24, wherein the cancer cell is a breast cancer  
15 cell.

29. The method of claim 22, wherein the peptide or mimetic comprises the sequence of SEQ ID NO:1.

30. The method of claim 22, wherein the peptide of mimetic comprises the sequence of SEQ ID NO:2.

31. The method of claim 22, wherein the peptide of mimetic comprises the sequence of SEQ ID NO:3.

5 32. A method of inhibiting BCL6 repression in a mammalian cell, the method comprising treating the cell with the compound of claim 1.

33. The method of claim 32, wherein the cell is a cancer cell.

34. The method of claim 33, wherein the cancer cell is a lymphoma cell.

10 35. The method of claim 33, wherein the cancer cell is a breast cancer cell.

36. The method of claim 32, wherein the cell is in a mammal.

37. The method of claim 36, wherein the mammal is a human.

38. The method of claim 32, wherein the peptide or mimetic comprises the sequence of SEQ ID NO:1.

15 39. The method of claim 32, wherein the peptide or mimetic comprises the sequence of SEQ ID NO:2.

40. The method of claim 32, wherein the peptide or mimetic comprises the sequence of SEQ ID NO:3.

41. A method of treating a mammal with cancer, wherein the cancer requires BCL6 repression, the method comprising administering the peptide or mimetic of claim 18 to the mammal.

42. The method of claim 41, wherein the mammal is a human.

5 43. The method of claim 41, wherein the cancer is a lymphoma.

44. The method of claim 41, wherein the cancer is a breast cancer.

45. The method of claim 41, wherein the peptide or mimetic comprises the sequence of SEQ ID NO:1.

10 46. The method of claim 41, wherein the peptide or mimetic comprises the sequence of SEQ ID NO:2.

47. The method of claim 41, wherein the peptide or mimetic comprises the sequence of SEQ ID NO:3.

15 48. A method of identifying a compound that inhibits corepressor binding to BCL6, the method comprising identifying a compound that binds to a BCL6 lateral groove, wherein a compound that binds to a BCL6 lateral groove inhibits corepressor binding to BCL6.

49. The method of claim 48, wherein the compound is an organic compound less than 1000 molecular weight.

50. The method of claim 48, wherein the compound is an aptamer.

51. The method of claim 48, wherein the compound is a peptide or peptide mimetic.

**Abstract**

Provided are peptides or mimetics that block corepressor binding to a BCL6 lateral groove. Also provided are methods of blocking corepressor binding to the BCL6 lateral groove. Additionally, methods of inhibiting BCL6 repression in a mammalian cell, and methods of treating a mammal with cancer are provided.

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Problem Image Mailbox.**

**FIG. 1**



# FIG. 2




FIG. 3






FIG. 4


A




B




C




D



E




F




# FIG. 5


**A**



**B**




**C**




**D**


$\alpha$ -BCL6       $\alpha$ -VP16      Overlay




**E**




# FIG. 6



# FIG. 7




**FIG. 8**




# FIG. 9


**A**




**B**



**C**



**D**



**FIG. 10**

